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The initial phases of atherosclerosis involve the transition of normal vascular smooth muscle 
cells (VSMCs) to a synthetic, dedifferentiated phenotype, which can migrate and proliferate. 
This could potentially obstruct blood flow, which, when destined to the cardiomyocytes, can lead 
to myocardial infarction. Studies have demonstrated that cardiomyocytes, undergoing apoptosis, 
release a phospholipid molecule called cardiolipin (CL) into the systemic circulation. The 
objective of this project was to investigate the impact of cardiolipin on VSMCs, specifically 
addressing cellular dedifferentiation, migration, proliferation, and whether these modifications 
are mitochondria-mediated. The effect of CL on aortic contractility was also examined. Using 
adult mice aortas, we quantified a number of differentiation and dedifferentiation markers (α-
smooth actin, calponin1, calpain I, and MMP14), following 48 hours of organ culture with 
physiological concentrations of CL (1µM and 10 µM) through immunoblotting. These CL 
concentrations were also used to investigate VSMC migration and proliferation over six days 
using cell culture, and to study blood vessel contraction following 48 hours of organ culture. 
Additionally, the acute effects of cardiolipin on VSMC mitochondria were examined through the 
use of high-resolution respirometry and selected substrate-inhibitor-uncoupler titration protocols. 
We found that calponin1 protein expression has significantly decreased by CL, while the other 
proteins remained unaffected. VSMC migration was ceased when treated with CL, while 
proliferation and contraction seemed unaffected. Mitochondrial respiration was significantly 
decreased for complex I and III. In conclusion, our results demonstrate that CL significantly 
reduces VSMC migration, calponin levels, and mitochondrial respiration, which could 
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Cardiolipin (CL) is a highly conserved (Mileykovskaya and Dowhan, 2009; Balasubramanian et 
al., 2015), negatively charged phospholipid molecule (Allegrini, 1984; Kates et al., 1993; Haines 
and Dencher, 2002; Lewis and Mcelhaney, 2009; Paradies et al., 2014). Unlike most 
phospholipids (Zhong et al., 2014), CL is composed of four fatty acyl chains, three glycerol 
units, and two phosphate molecules (Haines and Dencher, 2002; Houtkooper and Vaz, 2008; 
Zhong et al., 2014). CL resides in the inner mitochondrial membrane (Schlame and Haldar, 
1993; Hatch, 1998), where it provides structural support to the inner membrane and protein 
complexes (Gonzalvez and Gottlieb, 2007; Claypool et al., 2008; Singh et al., 2010; Paradies et 
al., 2014; Szeto, 2014; Planas-Iglesias et al., 2015). CL also acts as a proton trap (Haines and 
Dencher, 2002), and promotes mitophagy (Chu et al., 2013; Balasubramanian et al., 2015) by 
serving as an external signal on damaged mitochondria (Smith et al., 2011). CL triggers cellular 
apoptosis (McMillin, and Dowhan, 2002) as CL electrostatically anchors cytochrome c, which, 
when released, initiates downstream apoptotic cascades (McMillin and Dowhan, 2002; 
Tuominen et al., 2002). In many prokaryotes, CL acts as a pathogen defense mechanism against 
hosts’ immunity (Balasubramanian et al., 2015). Prokaryotic CL pairs with the extracellular 
lipopolysaccharides and acts to inhibit the production of macrophage cytokine (Balasubramanian 
et al., 2015). The involvement of CL in such functions indicates that its presence is highly 
regulated, and a disruption of CL content affects cells’ fate (McMillin, and Dowhan, 2002; 
Tuominen et al., 2002). Alteration in CL content is observed in various pathologies, including 
myocardial infarction (Vreken et al., 2000; Schlame and Ren, 2006; Dorio, et al., 2007; 
Nakajima et al., 2008; Goldmann and Medina, 2013).  
Myocardial infarction and subsequent ischemia trigger cardiomyocytes’ perforation, necrosis, 
and apoptosis, all of which release various intracellular components, including CL-positive 
membrane fragments (De Windt et al., 1998; Paradies et al., 1999; Lesnefsky et al., 2001; 
Carnevale and Bergdahl, 2015). Released CL affects neighboring cells, and elevates anti-CL 
antibodies in the blood circulation (Beauregard et al., 1980; Hamsten et al., 1986; Rossen et al., 
1994; Erta et al., 2013; Cernevale and Bergdahl, 2015). A recent study suggests that 
physiological concentrations of CL inhibit endothelial cell proliferation and microvessel 
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formation, contributing to anti-angiogenesis (Carnevale and Bergdahl, 2015). However, the 
effects of physiological concentrations of CL on vascular smooth muscle cells (VSMCs) were 
not yet been explored.  
Vascular Smooth Muscle Cells 
VSMCs are highly specialized (Zhang et al., 2015), differentiated cells that reside in the middle 
layer of the vascular walls, called tunica media, as well as in other hollow organ walls (Chiong, 
et al., 2013). Under normal physiological conditions, VSMCs express contractile proteins 
(Miano, 2003; Owens et al. 2004; Zhang et al., 2015) to regulate vasculature function (Chiong et 
al., 2013). VSMCs contract through various contractile proteins, such as myosin and α-actin 
(Fitridge, 2011; Shi and Chen, 2015). These proteins give VSMC its elongated, spindle-like shape, 
and allows it to contract, contributing to pressure regulation (Hellstrand and Albinsson, 2005; 
Fitridge, 2011; Chiong et al., 2013; Chiong et al., 2014; Shi and Chen, 2015). Differentiated 
VSMCs also have low migration, proliferation, and extracellular matrix secretory rates (Rzucidlo 
et al., 2007; Cecchettini et al., 2011; Chistiakov et al., 2015; Zhang et al., 2015). 
Unlike skeletal myocytes and cardiomyocytes, VSMC retain plasticity (Babaev et al., 1990; 
Bobryshev and Lord, 1996; Perry and Rudnick, 2000; Rzucidlo et al., 2007; Gomez and Owens, 
2012; Zhang et al., 2015), meaning they dedifferentiate from the contractile state to a synthetic 
phenotype in response to environmental cues (Gomez and Owens, 2012; Shi and Chen, 2015; 
Zhang et al., 2015). During vascular disease and injury (Campbell and Campbell, 1985; Owens 
GK., 1995; Rzucidlo et al., 2007; Cecchettini et al., 2011), inflammatory signals stimulate 
VSMC dedifferentiation in response to wound healing (Wang et al., 2006). Dedifferentiated 
VSMCs have high rates of DNA and protein synthesis and possess high rates of proliferation, 
migration, and extracellular matrix secretion (Rzucidlo et al.. 2007; Cecchettini et al., 2011; 
Fitridge, 2011), but low contractility (Campbell and Campbell, 1985; Gomez and Owens, 2012). 
These morphological and functional changes of VSMC are a result of altered expression of 
essential proteins, such as α-smooth muscle actin, calponin, calpain, and MMP14 (Owens et al., 





VSMC Protein Markers 
Actin filaments and myosin motors, as well as their associated proteins, make up the filamentous 
network in VSMCs that allows the cells to perform their mechanical functions in the vascular 
walls (Fritzsche, et al., 2013). α-actin is a conserved protein in mammals and in birds, and is 
expressed in VSMC (Perrin and Ervasti, 2010). α-actin makes up the actin microfilament bundles 
in VSMC and is involved in VSMC contraction (Hinz et al., 2001; Cherng et al., 2008; Lehman 
and Morgan, 2012; Yuan, 2015). Thus, disruption or degradation of α-actin proteins can affect 
vasculature elasticity and integrity (Schildmeyer et al., 2000; Suh et al., 2011; Fritzsche, et al., 
2013; Yuan, 2015). 
Calponin binds to α-actin to regulate VSMC contraction (Sugenoya et al., 2002; Cecchettini et 
al., 2011; Gomez and Owens, 2012). Calponin exists in three isoforms, of which only one, 
known as basic calponin or calponin-1, is expressed in differentiated VSMC (Jiang et al., 1997; 
Sugenoya et al., 2002). Calponin induces actin polymerization and stability, while it inhibits 
actin depolymerization (Jiang et al., 1997; Sugenoya et al., 2002). Calponin also inhibits myosin 
head ATPase activity (Sugenoya et al., 2002), and suppresses VSMC proliferation and DNA 
synthesis when overexpressed (Jiang et al., 1997; Sugenoya et al., 2002).  
Calpain is a conserved Ca2+-dependant protease that participates in intracellular signaling 
pathways (Yan et al., 2016). It promotes VSMC proliferation, migration, and differentiation, and 
is expressed during wound healing (Nassar et al., 2012). Inhibiting calpain’s activity reduces 
tissue damage in cardiovascular diseases (Nassar et al., 2012).  
MMP14 is a membrane-anchored matrix metalloproteinase that degrades extracellular matrix 
formed by VSMCs (Lehti et al., 2008). Upregulation of MMP14 protein expression is required 
for VSMC dedifferentiation and migration, which promotes neointimal formation (Lehti et al., 
2008; Yan et al., 2016). 
Upregulation of MMP14 and downregulation of α-actin, calponin, and calpain is observed in 
synthetic VSMCs, which allows the cells to migrate to the site of inflammation, proliferate and 
secrete extracellular matrix (Campbell and Campbell, 1985). This behavior contributes to the 





Cardiovascular diseases are diseases related to the heart and blood vessels, which account for 33 
deaths per minute, globally (American Heart Association, 2015). The major cause of 
cardiovascular diseases is atherosclerosis, which is the hardening and thickening of blood vessels 
(Noll, 1998; Guyton and Hall, 2006; Wick, 2012; Shi and Chen, 2015). During atherosclerosis 
development, factors such as cytokines trigger VSMC dedifferentiation and subsequent 
migration to the inflammatory area. Migrated VSMCs cannot return to their original location, 
which commits atherosclerosis to the irreversible stages of its development. 
Various risk factors are associated with atherosclerosis development, such as hyperlipidemia, 
hypertension, hyperglycemia, infections, gender, oxidative stress, genetics, tobacco smoke, and 
allergies (Noll, 1998; Bergmann and Sypniewska, 2011). Vascular regions that experience non-
uniform blood flow directionality, such as branch points and curvatures, are more prone to 
atherosclerosis development compared to unidirectional blood flow regions (Davies et al., 2010). 
This is because unidirectional blood flow induces a steady shear stress that evokes nitric oxide 
production, which in turn promotes vasodilation and anti-inflammation (Qiu et al., 2013). 
Unidirectional flow also downregulates pro-inflammatory and pro-VSMC dedifferentiation 
factors, such as interleukin-8 and vascular adhesion molecules (Goldman et al. 2007; Davies et 
al. 2013), while these factors are upregulated during non-uniform blood flow (Malek et al. 1999; 
Davies et al., 2013). All of these contribute to atherosclerosis formation, called atherogenesis, by 
evoking vascular endothelial damage, edema, or vasoconstriction.  
Stages of Atherosclerosis Progression 
Atherosclerosis is a slow progressive disease that develops in six main stages (Wick, 2012). 
During the first stage in atherogenesis, endothelial cells become damaged as these cells are in 
direct contact with the blood, making them the most susceptible cells to blood changes 
associated with the atherosclerotic risk factors (Simionescu and Sima, 2011). When the 
endothelial lining, called tunica intima, become damaged, low-density lipoproteins increase 
transcytosis (Simionescu and Sima, 2011), allowing low-density lipoproteins to translocate 
through the epithelia and accumulate in the sub-endothelial region (Guyton and Hall, 2006; Wick, 
2012), where they interact with matrix proteins and other factors, and become oxidized. These 
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modifications further increase endothelial cells’ permeability and adhesiveness (Simionescu and 
Sima, 2011). 
In the second stage, oxidized lipoproteins stimulate endothelin-1 generation, which triggers 
vasoconstriction and hypertension (Noll, 1998). Healthy endothelial cells generate anti-
atherogenic factors, such as nitric oxide, to inhibit platelet adhesion (Noll, 1998). Oxidized 
lipoproteins disrupt nitric oxide production, and cause further endothelial dysfunctions, such as 
increased expression of leukocyte-adhesion molecules and chemotactic factors that recruit 
leukocytes (Noll, 1998; Guyton and Hall, 2006; Wick, 2012). Nitric oxide also promotes VSMC 
relaxation, while inhibiting VSMC migration and proliferation. This results in vasodilation and 
healthy vasculature (Noll, 1998). Thus, during atherogenesis, endothelial damage and nitric 
oxide disruption promote vasoconstriction, platelet adhesion, as well as VSMC proliferation and 
migration at later stages (Noll, 1998). 
During the third stage, endothelial cytokines recruit platelets to the sub-endothelial injury site, 
where they attach to the endothelial binding molecules, become activated, and secret 
inflammatory cytokines that attract more platelets and leukocytes to the damaged area. 
Leukocytes, such as monocytes, are recruited, adhered, and translocated through the endothelia 
to the sub-endothelial injury site (Noll, 1998). Platelet-monocyte interactions form aggregates at 
the injury site, which triggers inflammatory responses (Noll, 1998; Guyton and Hall, 2006; Wick, 
2012) in the intima, where monocytes mature into macrophages via the influence of oxidized 
lipoproteins and cytokines. Macrophages engulf the modified lipoproteins and become foam 
cells, which are considered a hallmark of fatty streak lesion formation (Noll, 1998; Wick, 2012). 
During the fourth stage, foam cells release growth factors and cytokines that mediate VSMC 
switch from the contractile to the synthetic phenotype (Noll, 1998; Lacolley et al., 2012). These 
changes that occur in the sub-endothelial thicken the intimal layer and contribute to symptomatic 
coronary diseases.  
Stage five marks the beginning of the irreversible stage of atherosclerosis development. At this 
stage, dedifferentiated VSMCs migrate from the tunica media to the inflammatory site in the 
tunica intima, where they proliferate (Lacolley et al., 2012). Synthetic VSMCs secret 
extracellular matrix that stabilizes foam cells and hardens the plaque (Noll, 1998; Lacolley et al., 
2012). This causes the endothelial lining to become bulged into the vascular lumen, forcing 
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blood to pass through a narrower lumen, contributing to blood pressure elevation (Noll, 1998). 
Calcium ions are also withdrawn to the plaque’s site, calcifying the bulge, and increasing its 
stiffness and susceptibility of the plaque to rupture (Noll, 1998; Guyton and Hall, 2006). 
At stage six, macrophages and other leukocytes express inflammatory cytokines and proteases 
that digest the matrix, which cannot be replenished because VSMC collagen-synthesis becomes 
downregulated (Simionescu and Sima, 2011). This thins the fibrous cap and weakens the plaque, 
compromising the vascular wall’s ability to withstand high blood pressure (Simionescu and 
Sima, 2011). Blood flow against the plaque injures the endothelial cells and exposes the pro-
inflammatory and pro-coagulant factors within the extracellular matrix (Simionescu and Sima, 
2011). This, in turn, triggers platelets to further adhere to the injury site, where they become 
activated and form a thrombus. Depending on the thrombus site, myocardial infarction or stroke 
might occur, which could be lethal (Guyton and Hall, 2006; Wick, 2012). 
It is well-established that ischemia and heart failure are associated with CL loss and 
mitochondrial dysfunction (Paradies et al., 1999; Lesnefsky et al., 2001; Chicco and Sparagna, 
2006; Paradies et al., 2014). This led to shift research focus on mitochondria and its role in these 
pathologies.  
Mitochondria 
A mitochondrion is the ‘power plant’ organelle in eukaryotic cells (Chiong et al., 2014), 
consisting of an outer membrane and an inner membrane, separated by an intermembrane space. 
The inner membrane has a large surface area as it is highly crumpled into folds known as cristae, 
which are involved in ATP production through oxidative phosphorylation (Okumura et al., 1991; 
Scheffler, 2001; Heerdt et al., 2002; Paradies et al., 2014).  
Oxidative phosphorylation is the metabolic process that generates ATP in the presence of 
oxygen. Five complexes are involved in oxidative phosphorylation, complex I-V, which transfer 
electrons in a step-wise manner. NADH and FADH2, which are generated through glycolysis, 
fatty acid oxidation, and citric acid cycle, are energy-rich molecules that donate electrons to 
complex I and II respectively, and simultaneously mediating proton transfer from the 
mitochondrial matrix to the intermembrane space through complex I, III, and IV. Proton 
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accumulation in the intermembrane space generates a proton motive force that drives ADP 
phosphorylation to ATP via complex V, also known as ATP synthase.  
To generate ATP via oxidative phosphorylation, mitochondria first utilizes substrates derived 
from glucose and fatty acids via glycolysis and beta-oxidation in the cytosol. These processes 
ultimately produce Acetyl-coenzyme A, which is composed of two acetyl carbons that are bound 
to coenzyme A. Acetyl coenzyme A is an important molecule involved in cellular metabolism as 
it allows acetyl carbons to enter the citric acid cycle in the mitochondrial matrix (Paradies et al., 
2014). The citric acid cycle produces coenzymes (NADH and FADH2) that play key roles in 
generating large amounts of ATP in the electron transport chain complexes (Scheffler, 2001; 
Chiong et al., 2014). 
Mitochondria and Cardiolipin 
Mitochondria are fundamental organelles in eukaryotic cells. Mitochondrial respiration generates 
reactive oxygen species (ROS), whereas mitochondrial dysfunction can overproduce ROS 
(Zhong et al., 2014). ROS signals for automated cell death, thus is associated with 
neurodegenerative diseases, aging, and other pathologies (Chu et al, 2013; Zhong et al., 2014). 
To avoid this, eukaryotic cells have established a process to degrade defected mitochondria in 
order to preserve cells’ viability (Zhong et al., 2014). This process is known as mitophagy, 
which is not completely understood (Chu et al, 2013; Zhong et al., 2014).  
It was shown in cortical neurons and in SH-SY5Y cell line that an essential provoker of 
mitophagy is the externalization of CL from the mitochondrial inner membrane to the 
mitochondrial outer membrane (Chu et al, 2013). Different cells have different thresholds of 
externalized CL to induce mitophagy, but they seem to agree in concept (Chu et al, 2013). CL 
externalization is stimulated as a response to several pro-mitophagy factors, such as rotenone 
(Chu et al, 2013).  
Rotenone was found to increase the presence and the mitochondrial co-localization of the 
microtubule-associated-protein-1 light chain 3 (LC3), an autophagy protein. LC3 covalently 
binds CL and autophagosomes to mediate autophagy (Chu et al., 2013). LC3 also binds directly 
to the externalized CL of the cargo, signaling mitophagy and mediating mitochondrial 
engulfment (Chu et al., 2013). This indicates that rotenone is associated specifically with 
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increasing the mitochondria-targeted autophagy, mitophagy (Chu et al., 2013). LC3 presence is 
directly associated with autophagosomes (Chu et al., 2013). The cortical treatment with rotenone 
had increased the percentage of only CL, but not other phospholipids, in the mitochondrial outer 
membrane by ten-folds, relative to the basal CL amount of 0.8%. This shows that CL was 
externalized (Chu et al, 2013). In contrast to the well-studied lipids that become oxidized upon 
apoptosis, CL molecules are not peroxidized upon mitophagy, suggesting mitophagy occurs to 
prevent the accumulation of pro-apoptotic signals (Chu et al, 2013).   
In contrast to mitophagy, ROS oxidizes polyunsaturated CL acyl chains during apoptosis 
(Paradies et al., 2014; Zhong et al., 2014). CL oxidation is related to mitochondrial dysfunction, 
apoptosis regulation, and several pathologies (Zhong et al., 2014). Here we discuss CL-triggered 
apoptosis, and CL’s link to cytochrome c, a positively charged molecule (Kooijman et al., 2017). 
Cytochrome c is a mitochondrial protein involved in electron transfer from complex III to 
complex IV in the electron transport chain (Paradies et al., 2014; Ren et al., 2014). Cytochrome 
c plays an instrumental role in triggering apoptosis (Paradies et al., 2014) when it binds to CL 
(Chicco and Sparagna, 2006; Paradies et al., 2014).  
In the outer leaflet of the mitochondrial inner membrane, CL binds to cytochrome c (Ren et al., 
2014), which is a dormant peroxidase (Kooijman et al., 2017). Cytochrome c is anchored to the 
inner membrane through two CL binding sites, the A-site and the C-site (Paradies et al., 2014). 
The A-site binds to CL through electrostatic interactions (Chicco and Sparagna, 2006; Kapralov 
et al., 2007; Muenzner et al., 2013; Paradies et al., 2014), while the C-site binds to CL through 
hydrogen and hydrophobic interactions (Paradies et al., 2014; Zhong et al., 2014). The latter 
induces partial unfolding of cytochrome Met-80 residue from its associated heme-iron (Paradies 
et al., 2014). 
Peroxidized CL introduces conformational changes in cytochrome c and destabilizes the tertiary 
structure of its heme group (Paradies et al., 2014; Ren et al., 2014; Kooijman et al., 2017). This 
CL-cytochrome c complex pro-apoptotic peroxidase complex becomes activated, which further 
oxidizes CL (Kagan et al., 2005; Paradies et al., 2014; Ren et al., 2014; Kooijman et al., 2017). 
Oxidized CL, in turn, enhances the oxidation ability of the peroxidase (Paradies et al., 2014; Ren 
et al., 2014), which further oxidizes polyunsaturated in a continuous positive-feedback loop 
(Tyurina et al., 2006; Ren et al., 2014). The unfolded cytochrome c escapes to the cytosol, where 
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it activates cellular pathways that orchestrate apoptosis (Kagan et al., 2005; Chicco and 
Sparagna, 2006; Paradies et al., 2014; Zhong et al., 2014). The release of cytochrome c to the 
cytosol has been linked to permeabilizing the mitochondrial membrane, which facilitates the 
release of the apoptotic factors from the mitochondria (Belikova et al., 2007; Paradies et al., 
2009; Paradies et al., 2014), but this remains unclear (Kagan et al., 2005; Raemy and Martinou, 
2014). 
Several strategies have been studied to inhibit CL oxidation, which relates to atherosclerosis and 
other diseases (Zhong et al., 2014). Inhibiting the cytochrome c-CL peroxide complex inhibited 
apoptosis, and overexpressing lipid-reducing factor have lowered liver apoptosis, cytochrome c 
release, and CL oxidation (Zhong et al., 2014).  
It has been shown that under the sub-lethal threshold, ROS levels are enough to trigger CL 
translocation, but not CL peroxidation – a characteristic observed in mitophagy (Chu et al., 
2013; Ren et al., 2014). Thus, unoxidized CL is translocated from the inner to the outer leaflet of 
the mitochondrial inner membrane, rather than oxidized CL (Chu et al., 2013; Ren et al., 2014). 
Through this, mitophagy is initiated, but not apoptosis in sub-lethal mitochondrial injuries, 
preserving the cell’s viability (Chu et al., 2013; Ren et al., 2014).  
CL is also involved in structural support of the mitochondrial components. CL is negatively 
charged and have a long hydrophobic tail, allowing it to form strong ionic and hydrophobic 
interactions with neighboring molecules (Lewis and Mcelhaney, 2009; Paradies et al., 2014; Ren 
et al., 2014). CL tightly binds to the CL-affinity sites on the mitochondrial respiratory complexes 
I-V, via hydrophobic and ionic bonds (Eble et al., 1989; Lesnefsky et al., 2001; Claypool et al., 
2008; Singh et al., 2010; Paradies et al., 2014). 
Complex I, also known as NADH-ubiquinone oxidoreductase, is involved in electron transport 
from NADH to ubiquinone (Paradies et al., 2014), and is associated with CL (Chicco and 
Sparagna, 2006; Paradies et al., 2014). Complex I activity was lost upon CL loss in bovine heart 
and was only restored upon exogenous addition of CL (Paradies et al., 2014). 22% of CL loss 
have resulted in diminishing 15% of complex I activity in rat brains (Chicco and Sparagna, 
2006). CL oxidation by ROS has also been shown to inactivate complex I (Paradies et al., 2014). 
This effect was encountered upon the addition of exogenous CL (Paradies et al., 2014).  
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Complex II, also known as succinate dehydrogenase, oxidizes succinate from the Krebs cycle 
and provides electrons to the electron transport chain (Paradies et al., 2014). The presence of CL 
in the phospholipid environment of complex II is required for the stability and enzymatic activity 
for the complex (Paradies et al., 2014). CL presence around complex II seems to restrict ROS 
production, even though this remains unclear (Paradies et al., 2014).  
CL stabilizes the quaternary structure of complex III, also known as ubiquinol cytochrome c 
oxidoreductase (Haines and Dencher, 2002; Chicco and Sparagna, 2006; Paradies et al., 2014). 
Multiple CL molecules bind to complex III to stabilize and maintain its enzymatic activity 
(Haines and Dencher, 2002; Paradies et al., 2014). In the absence of CL, the complex was 
destabilized and its enzymatic activity was significantly diminished (Haines and Dencher, 2002; 
Chicco and Sparagna, 2006; Paradies et al., 2014). CL oxidation by ROS have also deactivated 
complex III (Paradies et al., 2014). Complex III full activity and stability were rescued only upon 
the administration of CL, signifying the importance of CL and its association to complex III 
(Paradies et al., 2014). 
Complex IV, also known as cytochrome c oxidase, tightly binds to three CL molecules through 
CL-specific binding sites (Paradies et al., 2014). The complex’s binding to unsaturated CL 
molecules promotes for its optimal enzymatic activity (Lesnefsky et al., 2001; Haines and 
Dencher, 2002; Chicco and Sparagna, 2006; Paradies et al., 2014). Absence of CL has been 
shown to destabilize complex IV and reduced its activity (Paradies et al., 2014). CL peroxidation 
by ROS also inactivated complex IV (Paradies et al., 2014). Its activity was rescued upon the 
addition of exogenous CL (Paradies et al., 2014). 
Complex V, also referred to as F0F1 ATP-synthase, uses proton gradient-derived energy to 
phosphorylate ADP to ATP (Paradies et al., 2014). In complex V, at least four sites were found 
to bind exclusively to CL with high affinity (Eble et al., 1989; Chicco and Sparagna, 2006; 
Paradies et al., 2014). Even though the exact contribution of CL to complex V is not yet well 
studied, but it is evident that CL supports the enzymatic activity of complex V (Haines and 
Dencher, 2002). The removal of phospholipids surrounding complex V have significantly 
diminished its activity, and the restoration of complex V activity was more effective upon the 
addition of CL compared to other phospholipids (Paradies et al., 2014).  
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It has also been shown that CL is associated with numerous other proteins and that it is required 
for their optimal enzymatic activities (Eble et al., 1989; Paradies et al., 2014). These proteins 
include: mitochondrial glycerol-3-phosphate dehydrogenase, the phosphate transporter, 
ADP/ATP carrier protein (Beyer and Klingenberg, 1985; Eble et al., 1989; Haines and Dencher, 
2002; Chicco and Sparagna, 2006; Claypool et al., 2008; Paradies et al., 2014; Ren et al., 2014), 
mitochondrial creatine kinase, carbamoyl phosphate synthetase I, carnitine/acylcarnitine carrier, 
nucleoside diphosphate kinase, phosphate transporter, pyruvate transporter, tricarboxylate carrier 
(Chicco and Sparagna, 2006; Paradies et al., 2014). The binding sites and the affinity of CL to 
these proteins have not yet been determined (Eble et al., 1989; Chicco and Sparagna, 2006; 
Paradies et al., 2014). 
In our lab, CL was found to inhibit endothelial cell proliferation and migration (Carnevale and 
Bergdahl, 2015). Endothelial cells are involved in angiogenesis, a physiological process that 
forms new capillaries from pre-existing blood vessels. Angiogenesis is important during 
ischemic conditions to promote healing (Carnevale and Bergdahl, 2015). This process was 
significantly suppressed by the addition of physiological CL concentrations in a dose-dependent 
manner (Carnevale and Bergdahl, 2015). This indicates that CL has anti-proliferative properties 
on vascular endothelial cells, and that CL disrupts endothelial cells migration and degradation of 
the basement membrane (Carnevale and Bergdahl, 2015).  
Project Overview 
Excluding work done in our lab, all previous studies that involved CL were based on eliminating 
CL. Alternatively, we decided to explore the effects of adding physiological concentrations of 
CL. Specifically, to study the effects of CL on VSMCs, as these cells determine the progression 
of atherosclerosis into the irreversible stages, and because the link between CL and VSMC has 
not been explored before.  
Thus, we studied the effects of physiological concentrations of CL on VSMC phenotypic protein 
markers, as well as its effect on VSMC bioenergetics and aortic contraction. We hypothesized 
that CL would inhibit VSMC proliferation and migration as it did in endothelial cells. 
Consequently, we expected CL to downregulate VSMC dedifferentiation markers and upregulate 
15 
 
VSMC differentiation markers. Due to the involvement of mitochondria in various cellular 
functions, we expected that acute addition of CL would affect mitochondrial bioenergetics.  
Techniques 
In situ and ex-vivo studies were performed on adult male mice aortic tissues to study the effects 
of physiological concentrations of CL. The effect of CL on VSMC phenotypic switch was 
studied by quantifying various differentiation and dedifferentiation markers using 
immunoblotting. We also studied the effect of CL on VSMC migration and proliferation rates 
using migration and proliferation assays. Given that CL resides in the mitochondria, we 
suspected that CL addition affects mitochondrial activity. Thus, we studied VSMC mitochondrial 
respiration using the high-resolution respirometry technique. To test whether CL has an effect on 
the overall function of the aortic tissue, isometric force measurement was used to examine aortic 
contractility. CL used in these experiments was derived from bovine heart as CL is highly 
conserved across species (Chicco and Sparagna, 2006). 
Immunoblotting 
Immunoblotting, also referred to as Western blotting, is a technique used to quantify proteins 
using antibodies. We used immunoblotting to determine the amount of differentiation and 
dedifferentiation markers present in VSMCs following organ culture incubation for 48 hours at 
37oC in 0µM, 1µM, and 10µM CL. 
To extract the proteins of interest from VSMCs in the aortas, we used lysis buffer and physical 
force to lyse the vessels and release their protein content. This lysis mixture was then centrifuged 
and the pellets were discarded, while the supernatants were preserved for the study.  
To prevent the protein tertiary structure from interfering with the protein migration distance 
during the electrophoresis separation stage, we pipetted DTT into the samples to break the 
protein disulfide bridges.  
The samples were loaded into the electrophoresis gel wells along with a standard protein ladder, 
which allows us to identify the approximate distance travelled by the proteins. The gel was 
supplied with electric current to separate the proteins according to their size. Proceeding protein 
migration, the bands were transferred from the gel into a cellulose membrane, and the membrane 
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was stained with Ponceau dye to visualize the protein bands. The membrane was then immersed 
in blocking buffer to decrease the background interference. To achieve the first stage of labeling 
and quantifying the proteins of interest, the membrane was incubated in a buffer solution 
containing primary antibodies that are specific to these proteins’ epitopes. Excess primary 
antibodies were washed off, and the membrane was incubated with secondary antibodies. The 
secondary antibodies are specific to the epitopes of the primary antibodies. Multiple secondary 
antibodies can bind one primary antibody, which amplifies the antibody tag per protein. Because 
antibodies are invisible, the membrane was immersed in ECL solution, which is a fluorescence 
solution that tags secondary antibodies. Signals emitted from the ECL-containing bands were 
detected by a light-sensitive, silver-based film, which was then developed and scanned to 
quantify the bands.  
Tissue Preparation for Migration and Proliferation 
Under a light microscope, fat streaks surrounding the aortas were detached under a dissection 
microscope, then the aortas were bilaterally dissected, and the endothelial cells were gently 
scraped off, while the VSMC-containing layer was plated. 
Migration Assay 
Migration assay is a technique used to assist cell migration rate. VSMCs present along the 
diameter of the confluent plates were scraped off and supplied with serum-free media (Jones et 
al., 1993) containing 0 µM, 1 µM, and 10 µM CL. The serum-free media restricts VSMC 
proliferation, eliminating this parameter from interfering with the migration results. The scrapes 
were observed under phase-contrast microscopy and the width of the scrapes were blindly 
measured.  
Proliferation Assay 
Proliferation assay is a technique used to measure the amount of viable cells over time. Plated 
cells were supplied with media containing 0 µM, 1 µM, and 10 µM CL. The cells were detached 





High-resolution respirometry is often used to study mitochondrial respiration in isolated, highly-
oxygenated chambers. This technique requires permeabilized samples (Pesta and Gnaiger, 2012) 
to measure the overall mitochondrial respiration performance by calculating samples’ respiration 
rate, which is the rate at which mitochondria consume oxygen and convert ADP to ATP, through 
measuring oxygen consumption level, i.e. the drop in oxygen level in the isolated chamber 
(Kuznetsov, 2008). The tissues were treated with 0 µM, 1 µM, and 10 µM CL acutely, and the 
performance of individual phosphorylation complexes can be assessed by using a stepwise 
multiple substrate-uncoupler-inhibitor titration protocols (Pesta and Gnaiger, 2012). This method 
provides a deeper insight into the samples’ metabolism and physiology, narrowing down to the 
complexes that might be involved in a mitochondrial defect in case of a dyscoupling when 
compared to control specimens (Pesta and Gnaiger, 2012).  
Isometric force measurement 
To assist the functional implications of CL on aortic contraction, we used the isometric force 
measurement technique. The aortas incubated in 0 µM, 1 µM, and 10 µM CL with were mounted 
on a myograph, where two wires pass through the vessel. One wire connects to a micrometer 
screw to restrict the wire movement. The second wire is free to move and is connected to a force 
transducer to measure the force that the vessel generates upon its contraction. High potassium 
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The initial phases of atherosclerosis involve the transition of normal vascular smooth muscle 
cells (VSMCs) to a synthetic, dedifferentiated phenotype, which can migrate and proliferate. 
This potentially obstructs blood flow, which, when destined to the cardiomyocytes, can lead to 
myocardial infarction. Studies have demonstrated that cardiomyocytes, undergoing apoptosis, 
release a phospholipid molecule called cardiolipin (CL) into the systemic circulation. The 
objective of this project was to investigate the impact of cardiolipin on VSMCs, specifically 
addressing cellular dedifferentiation, migration, proliferation, as well as aortic contractility. 
Using adult mice, we quantified a number of differentiation and dedifferentiation markers (α-
smooth actin, calponin, calpain, and MMP14), following 48 hours of organ culture with 
physiological concentrations of CL (1µM and 10 µM). These CL concentrations were also used 
to investigate the migration and proliferation of VSMCs over six days using cell culture, and 
blood vessel contraction following 48 hours of organ culture. We found that calponin protein 
expression has significantly decreased by CL addition, while the other proteins remained 
unaffected. VSMC migration was ceased when treated with CL, while proliferation and 
contraction were non-significantly affected. In conclusion, our results demonstrate that CL 








Cardiolipin (CL) is a conserved (Mileykovskaya and Dowhan, 2009; Balasubramanian et al., 
2015) phospholipid molecule with an approximate half-life of 2 days in rodent cardiomyoblast 
(Zachman et al., 2010; Xu and Schlame, 2014). CL resides in the inner mitochondrial membrane 
(Schlame and Haldar, 1993; Hatch, 1998), where it provides structural support to the membrane 
(Szeto, 2014) and its protein complexes (Gonzalvez and Gottlieb, 2007; Claypool et al., 2008; 
Singh et al., 2010; Paradies, 2014). CL electrostatically anchors cytochrome c, which, when 
released, initiates downstream apoptotic cascades (McMillin and Dowhan, 2002; Tuominen et 
al., 2002). The involvement of CL in such functions indicates that its presence is highly 
regulated, and a disruption of CL content affects cell fate (McMillin and Dowhan, 2002; 
Tuominen et al., 2002).  
Myocardial infarction and subsequent ischemia trigger perforation, necrosis, and apoptosis of 
cardiomyocytes, consequently releasing various intracellular components, including CL-positive 
membrane fragments (Chicco and Sparagna, 2006; Carnevale and Bergdahl, 2015). Released CL 
affects neighboring cells and elevates anti-CL antibodies in the blood circulation (Beauregard et 
al., 1980; Hamsten et al., 1986). A recent study suggests that physiological concentrations of CL 
inhibits endothelial cell proliferation and microvessel formation, contributing to anti-
angiogenesis (Carnevale and Bergdahl, 2015). However, the effects of physiological 
concentrations of CL on vascular smooth muscle cells (VSMCs) were not yet been explored. 
VSMCs are highly specialized, differentiated cells that reside in the middle layer of the tunica 
media (Hellstrand and Albinsson, 2005; Zhang et al., 2015). Under normal, physiological 
conditions, VSMCs express contractile proteins, which regulate vasculature function (Miano, 
2003; Owens et al., 2004; Chiong et al., 2013; Chistiakov et al., 2015; Zhang et al., 2015). 
VSMC contractibility is required for vascular elasticity and contributes to blood pressure 
maintenance. VSMC contraction involves many pathways and that depends on actomyosin force, 
as well as on Ca2+ influx, which upregulates some contractile proteins through binding to their 
transcription factors (Brozovich et al., 2016).  
In addition, VSMCs retain plasticity (Babaev et al., 1990; Bobryshev and Lord, 1996), meaning 
they switch from contractile to synthetic phenotype in response to environmental cues (Gomez 
and Owens, 2012; Shi and Chen, 2015; Zhang et al., 2015) during vascular disease and injury 
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(Campbell and Campbell, 1985; Rzucidlo et al., 2007; Cecchettini et al., 2011). Dedifferentiated 
VSMCs have high rates of DNA and protein synthesis (Fitrifge, 2011), and possess high rates of 
proliferation, migration, and extracellular matrix secretion (Rzucidlo et al., 2007; Lehti et al., 
2008; Cecchettini et al., 2011; Lacolley et al., 2012; Brozovich et al., 2016), but low contractility 
(Campbell and Campbell, 1985; Gomez and Owens, 2014). Proteins, such as MMP14, calpain, 
calponin, and α-smooth muscle actin, participate in these morphological and cellular functions 
(Owens et al., 2004; Rzucidlo et al., 2007; Lehti et al., 2008; Cecchettini et al., 2011).  
Dedifferentiated VSMC also proliferates during vascular wall remodeling, as well as during 
atherosclerosis development. Proliferation proceeds through the cell cycle, and is finalized by 
cytokinesis through actomyosin force. 
Furthermore, cell migration is needed for VSMCs during inflammatory responses and vascular 
inflammation (Bunnell et al., 2011; Artman et al., 2014). VSMC migration occurs as a result of 
cytoskeletal movement through actin microfilament remodeling and its association with myosin 
II, which plays an early role in VSMC migration by aligning the cytoskeletal actin bundles, 
maintaining their length, and establishing cell polarity (Artman et al., 2014; Brozovich et al., 
2016).  
Because CL was found to inhibit endothelial cell migration and proliferation, we hypothesize 
that VSMC migration and proliferation can also be inhibited by CL addition. Given the 
involvement of actins in VSMC contraction, migration, and proliferation, we hypothesize that 
CL could disrupt calponin1 or actin expression, which would lead to a restriction in the 
contraction, migration, and proliferation ability of VSMCs. Thus, we quantified VSMC protein 
markers and tested for VSMC functions using various techniques.  
Methods 
Animal Care 
Male C57B1/6 mice, 7-8 months old were obtained from the breeding colony at Concordia 
University, and randomly assigned to either control, 1 μM CL, or 10 μM CL groups. The mice 
were kept on a 12:12 h photoperiod at a thermos-neutral environment (22oC), and had free access 
to standard dry rodent chew and water. All procedures were approved by the Animal Ethics 
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Committee of Concordia University (Ethics: #30000259) and were conducted according to the 
Canadian Council on Animal Care guidelines. 
Tissue Extraction 
The mice were euthanized in CO2 according to the animal ethics protocol. The abdominal cavity 
and the thorax were exposed, and the aortas were extracted by cutting the connective tissues 
along the spine. The aortas were kept on ice in tubes containing physiological salt solution 
(nominally Ca2+-free Krebs sterile solution containing (135.5 mM NaCl; 5.9 mM KCl; 1.2 mM 
MgCl2; 11.6 mM glucose; 11.6 mM HEPES; pH 7.35, penicillin 100 U/ml and streptomycin 100 
Ig/ml). Fat streaks and connective tissues surrounding the vessels were detached under a 
dissection microscope.  
Immunoblotting Tissue Preparation 
The dissected, cleaned samples were placed in DMEM/F-12 media plates containing 0 µM, 1 
µM, and 10 µM CL, and incubated at 37oC under 5% CO2 for 48 hours (corresponding to CL’s 
half-life) (Xu and Schlame, 2014). Post-incubation, the aortas were bilaterally dissected and the 
endothelial cell layer was gently scraped off with a sponge, leaving behind only the VSMC-
containing layer. 
Immunoblotting 
To extract cell lysate, the aortic tissues were grinded in 1β0 μl lysis buffer (250 mM NaCl; 50 
mM HEPES; 10% glycerol; 1% trion X-100; 1.5 mM MgCl2; 1 mM EGTA; 10 mM Na4P2O7; 1 
mM NaF; 800 μM Na3VO4). The lysis mixture was centrifuged at 13000 rpm for 10 minutes, and 
the supernatants were preserved for the study. β0 μl of the lysate was mixed with β μl DTT (1M 
1,4-dithio-DL-threitol, D0632-5G, Sigma-Aldrich; 10mM sodium acetate; pH 5.β) and 4 μl of 
sample buffer (347 mM SDS; 0.25 M Tris, pH 6.8; 1.49 mM bromophenol blue, 501 mM DTT; 
6.84 M glycerol). The mixture was incubated at 37oC for 20 minutes, then separated on 10% 
SDS-PAGE along with a standard ladder in running buffer (2.27 M Tris base; 17.5 M glycine; 
315 mM SDS; pH 8.3), and subsequently transferred to a nitrocellulose membrane (0.45 μm, 
Bio-Rad, Germany) in sodium tetraborate decahydrate solution (10 μM, Sigma-Aldrich, St. 
Louis, MO) for 40 minutes on 120 mV. The protein bands in the membrane were visualized 
using Ponceau dye (1.49 mM Ponceau; 0.87 mM acetic acid) and then scanned to quantify the 
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proteins in each lane using Image J software. The membranes were blocked with 5% skimmed 
milk in 0.1% TBS-T (0.1% of 0.1 M Tris-base and 1.5 M NaCl; 1 ml Tween-20, 0777-1L, VWR 
International, Solon, OH) for 1 hour, then the membranes were incubated with primary 
antibodies diluted in 0.1% TBS-T at 4oC overnight. Primary antibodies used: anti-α-actin 
(1:2000, Ab7817 Abcam); anti-calponin (1:20,000, ab46794 Abcam); anti-calpain (1:2000, 
ab28258 Abcam); anti-MMP14 (1:2000, ab3644 Abcam). The membranes were then washed in 
0.1% TBS-T for 3 x 10 minutes, then incubated in secondary antibodies for 1 hour at room 
temperature. Secondary antibodies used: ab6721 Abcam rabbit polyclonal for MMP14, calponin, 
calpain; and ab67β8 Abcam mouse monoclonal for α-actin. The membranes were re-washed in 
0.1% TBS-T for 3 x 10 minutes. The membranes were covered with ECL fluorescence solution 
(Amersham ECL Western Blotting Detection Reagents; RPN2106; GE Healthcare, UK) for 6 
minutes, and the films were developed and the bands were analyzed using Image J software. 
Each protein was tested for n = 9 - 12.  
Tissue and Culture Preparation for Migration and Proliferation 
The dissected, cleaned samples were bilaterally cut-open, the endothelial cells were gently 
scraped off with a sterilized metal surface. The sample tissues were further cut into small pieces 
(approximately 0.5 cm2), mixed, and randomly placed (under sterile conditions in a biological 
safety cabinet) on multiple media-containing Petri dishes: (DMEM/F-12, 1:1, with serum and 
antibiotics). The plates were then kept in an incubator at 37oC under 5% CO2 in the air and the 
cells were allowed to grow to confluency (approximately 1 week). Next, the plates were 
trypsinized (0.05% Trypsin, 0.53 mM EDTA; 25-052-Cl; Corning, Manassas, VA, USA) in a 
biological safety cabinet. The media in the plates was pipetted out, and its traces were washed 
away with PBS solution (1.36 M NaCl, 26.8 mM KCl, 101.4 mM Na2HPO4, 17.6 mM KH2PO4, 
pH 7.4). Approximately 4 ml of trypsin-EDTA was added to the plates and incubated at 37oC for 
about 8 minutes. Trypsin was neutralized with DMEM/F-12 media (approximately 4 ml) and the 
cell mixture was centrifuged at 3500 rcf for 6 minutes. The supernatant was discarded and the 




Around 0.5 ml of the cell suspension was added to P15.6 plates, which were supplemented with 
1 ml DMEM/F-12 media and the cells were allowed to reach confluency at 37oC under 5% CO2 
in air for a week. Cells that align the diameter of the plates were scraped off using a sterile P100 
micropipette tip, making a horizontal strip on the plates’ bottom. Then the media was exchanged 
for 0 µM, 1 µM, and 10 µM CL in serum-free media (six plates per condition). The serum-free 
media keeps the cells differentiated, as well as it restricts the cells from proliferating, limiting 
and observed changes to migration but not proliferation. The width of the scrapes were observed 
under phase-contrast microscopy and (approximately 10) images were captured per plate every 
48 hours for 6 days, and the width of the scrapes, or the “wounds,” were blindly measured 
(Approximately 3 measurements per image).  
Proliferation Assay 
120 µl of the cell suspicion solution was added onto P60 plates, which were further 
supplemented with 1.5 ml DMEM/F-12 media. The cells were incubated at 37oC under 5% CO2 
in air for 1-2 days to attach to the plates and grow. The media was then exchanged for DMEM/F-
12 media containing 0 µM, 1 µM, and 10 µM CL. The plates were trypsinized (in the same 
manner as in the migration assay) every 48 hours for six days, and the cells were counted using a 
hemocytometer under a phase-contrast microscopy. This was done for n = 3.  
Isometric force measurement 
Aortas cleaned from fat streaks were mounted on a wire myograph in high sodium solution, 
which consists of (in mM): NaCl 135.5, KCl 5.9, CaCl2 2.5, MgCl2 1.2, glucose 11.6, HEPES 
11.6, pH 7.35. The wires were set to 700 mg basal tension, which is considered within the 
optimal resting tension range to obtain the maximal contractile tension when the muscle is 
induced to contract by high potassium solution (Jiang et al, 1999). The high sodium solution was 
exchanged to high potassium solution, which consists of (in mM): KCl 141.4, CaCl2 2.5, MgCl2 
1.2, glucose 11.5, HEPES 11.6, pH 7.35. The muscle contraction was recorded for 7 minutes, 
and then the high potassium solution was exchanged back to high sodium solution until the 
readings stabilized. This was repeated and a second high potassium reading was measured. Upon 






Table 1 depicts images of scraped VSMC plates incubated in control, 1 µM and 10 µM CL 
treated media. The snapshots were taken every 48 hours for six days. The images show that the 
induced gap has decreased more in the control plates compared to the CL-treated plates.    
Scraped VSMC plates 



















         Table 1. Scraped VSMC culture plates. Images of scraped VSMC culture plates taken every 48 hours for six days in control, 1 µM         
.        and 10 µM CL treated media. The images show that the induced gap has decreased significantly in the control plates compared to the      
.        CL-treated plates. Six plates were prepared per condition, and approximately 10 images were captured per plate, and each image was .          
.        analyzed at 3 distinct regions. Therefore, n-value is approximately = 180. Images captures under total magnification of x100.  
Figure 6 depicts an overall increase in cell proliferation for the control, 1 μM CL, and 10 μM CL 
groups. However, there was no significant difference between the three groups as revealed by the 





Figure 6. Proliferation Assay. VSMC Proliferation rate as CL concentration increases from 0 to 10 μM. There was 
no significant difference in proliferation in the presence or absence of CL. This graph represents n=3. Standard Error 
Mean measurement was used to calculate the error bars. 
Figure 7 depicts no significant difference in the maximal high-potassium contraction force 
between any of the three groups, with ANOVA p-value > 0.05. Our results (data not shown) also 
depicts no significant change in the endotheline-1-induced contraction in any of the three groups 
(ANOVA p > 0.05). 
 
Figure 7. Aortic Contraction. Vessel contraction force as CL concentration increases from 0 to 10 μM. There was 
no significant difference in aortic contraction force in the presence or absence of CL. This graph represents n = 11 
for 1 μM CL treated samples, and n = 1γ for control and 10 μM treated samples. Standard Deviation measurements 




CL is the only phospholipid molecule that is significantly released out of the mitochondria upon 
cell perforation (De Windt et al., 1998; Paradies et al., 1999; Lesnefsky et al., 2001). The recent 
discovered role of CL on endothelial cells (Carnevale and Bergdahl, 2015) has led us to study the 
effect of CL on VSMCs dedifferentiation, migration, and proliferation. We also studied the 
functional implications of CL on mice aorta. SMCs are the only myocytes that retain plasticity 
and can change morphology due to altered expression of essential proteins, such as MMP14, 
calpain, calponin, and α-smooth muscle actin (Owens et al., 2004; Rzucidlo et al., 2007; Lehti et 
al., 2008; Cecchettini et al., 2011). We studied the expression of these proteins as they would 
provide a wide spectrum of the effect of CL on VSMCs since MMP14 is a dedifferentiation 
marker, while calponin, calpain, and α-actin are differentiation markers. These proteins also vary 
in their turnover rates, providing an insight of CL’s effects on these proteins’ expression. 
MMP14 is a membrane-anchored matrix metalloproteinase that degrades extracellular matrix 
formed by VSMCs (Lehti et al., 2008). MMP14 expression upregulation is required for VSMC 
dedifferentiation, and migration, which promotes neointimal formation (Lehti et al., 2008; Yan et 
al., 2016). MMP14 has an mRNA half-life of 26-27 hours in rat microvascular endothelial cells, 
while its mature, activated protein has a half-life of 1 hour (Litwack, 2009). Expression of 
MMP14 is upregulated in dedifferentiated VSMCs (Lehti et al., 2008). Despite the slight 
increasing trend observed as CL concentration increased, our results reveal no significant 
difference in MMP14 quantity in any of the CL groups versus the control group. This suggests 
that CL does not suppress MMP14 protein expression because if it did, MMP14 (at least its 
active form) would have had enough time to be degraded. Since MMP14 protein quantity 
remained stable throughout the experiment in all three conditions and that its expression would 
have increased in dedifferentiated VSMCs, we concluded that CL does not promote VSMCs 
dedifferentiation.  
Calpain I, which has a half-life of 5 days in WI-38 human diploid fibroblasts (Zhang et al., 
1996), is a conserved Ca2+-dependant protease that participates in intracellular signaling 
pathways. Calpain I is expressed during wound healing as it promotes VSMC proliferation, 
migration, and differentiation (Nassar et al., 2012). Consequently, inhibiting calpain activity 
reduces tissue damage in cardiovascular diseases (Nassar et al., 2012). Our results reveal that 
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calpain’s quantity remained unchanged upon VSMCs incubation in CL-containing media 
compared to control, even though an increasing pattern was observed at increasing CL 
concentrations. This further suggests that CL does not induce VSMC dedifferentiation upon 
incubation for 2 days. 
Calponin1, which has an mRNA half-life of 16 hours in human mesangial cells (Sugenoya et al., 
2002; Owens et al., 2004; Rzucidlo et al., 2007; Cecchettini et al., 2011), exists in three 
isoforms, of which only one, known as basic calponin or calponin1, is expressed in differentiated 
VSMCs (Jiang et al., 1997; Sugenoya et al., 2002). The expression of calponin1 has significantly 
dropped in a dose-dependent manner upon increasing concentrations of CL. Since actin-
associated proteins have a half-life of 4-5 days (Hossain et al., 2006), and that our calpain and 
MMP14 data suggest that CL does not cause VSMC dedifferentiation and that MMP14’s half-
life is shorter than calponin’s, the drop in calponin1 quantity indicates a specific effect of CL on 
calponin1. Thus, we further examined the functions that calponin1 inhibition could potentially 
affect.  
Calponin1 associates with actin, whose monomers, referred to as G-actins, are proteins that 
polymerize to form a filamentous structure, known as F-actin (Artman et al., 2014). Actin 
filaments are required for many cellular functions, such as vesicle trafficking, cell shape, cell 
proliferation, chromatin organization, cell migration, and contraction (Perrin and Ervasti, 2010; 
Almuzzaini et al., 2016). In mammals, there are six isoforms of actin, some are muscular and 
some are not, where each participates in different tasks (Perrin and Ervasti, 2010; Yuan, 2015).  
α-smooth actin, which is a muscular actin, has a half-life of 72 hours in human myofibroblasts 
(Sugenoya et al., 2002; Baouz, 2005). α-actin is a conserved protein in mammals and birds, and 
is strongly expressed in differentiated VSMCs (Perrin and Ervasti, 2010). α-smooth actin makes 
up the actin microfilament bundles (Cherng et al., 2008; Lehman and Morgan, 2012; Yuan, 
2015), which are associated with myosin and other proteins (Fritzsche, et al., 2013). This α-
actinomyosin filamentous network is involved in VSMCs contractility (Owens et al., 2004; 
Rzucidlo et al., 2007; Hinz et al., 2001; Cecchettini et al., 2011; Yuan, 2015). This led us to 
quantify α-actin and measure aortic contractility. Our data shows that α-actin quantity is 
unaffected by the addition of CL, further suggesting that CL does not initiate VSMC 
dedifferentiation and that the effect of CL is calponin-specific. Our isometric force measurement 
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results indicate that the aorta maximum contractibility created by high K+ or endotheline-1 (data 
not shown) was unaffected by its incubation in CL-containing media for 48 hours. This supports 
our conclusion that CL affects neither α-actin’s quantity, nor its contractile function in aortas, 
even though we observed an increasing trend in VSMC maximum contractility. This trend could 
be explained by the potential increase in myosin ATPase function as myosin ATPase inhibition 
decreases as calponin level decreases, leading to more or stronger contractions (Jiang et al., 
1997). The contractions induced by endothline-1, which is a potent vasoconstrictor, are not 
significant with no apparent trend (data not shown). This also excludes the possibility that CL 
affects α-actin or aortic contraction. Since calponin is involved in α-actin polymerization and that 
CL decreases calponin’s level but not α-actin’s, it is possible that there might be another player 
that compensates for calponin’s reduction and α-actin polymerization.  
Calponin also associates with ȕ-actin, which has a half-life of approximately 2 days (Cheever et 
al., 2011). ȕ-actin is a non-muscular, cytoplasmic actin molecule (Jiang et al., 1997; Artman et 
al., 2014). ȕ-actin monomers are involved in regulating gene expression as they interact with 
RNA polymerases and chromatin-remodeling complexes (Bunnell et al., 2011). ȕ-actin inhibits 
the serum response factor gene-regulatory pathway that regulates the expression of G-actins and 
actin-binding proteins (Bunnell et al., 2011). ȕ-actin polymerizes to form cytoskeletal 
microfilaments involved in cell migration and cell proliferation (Almuzzaini et al., 2006; Perrin 
and Ervasti, 2010; Artman et al., 2014).  
To maintain the cellular functions α- and ȕ-actin participate in, the levels of these actins as well 
as their polymerization and depolymerization rates, must be regulated. calponin1 induces actin 
polymerization and actin thin-filament stability, while it inhibits their depolarization (Jiang et al., 
1997; Sugenoya et al., 2002). It also inhibits myosin ATPase activity and lowers the actin 
filament translocation rates towards myosin (Jiang et al., 1997). Calponin1 also inhibits cell 
division signaling, which contributes to diminishing DNA synthesis and cell proliferation in 
muscular and non-muscular cells (Jiang et al., 1997; Sugenoya et al., 2002), although the exact 
mechanism remains incompletely understood (Jiang et al., 1997). Thus, a disruption in calponin1 
level impacts ȕ-actin monomer: polymer balance, as well as their actomyosin functions, such as 
migration and proliferation (Jiang et al., 1997; Schildmeyer et al., 2000; Suh et al., 2011; 
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Fritzsche, et al., 2013). Thus, we decided to study the effect of CL of these two functions in 
VSMCs (Yuan, 2015). 
VSMC migration is initiated during vascular inflammation and is required for the repair process 
(Artman et al., 2014). VSMC migration is accomplished through cytoskeletal movement, which 
is based on the constant ȕ-actin microfilament remodeling and its association with myosin II, 
which plays an early role in VSMC migration (Artman et al., 2014; Brozovich et al., 2016). 
VSMC migration is initiated by receiving pro-migratory external signals, which trigger myosin II 
to align the cytoskeletal ȕ-actin bundles, maintain their length, and establish cell polarity 
(Artman et al., 2014; Brozovich et al., 2016). These signals also initiate cytoskeletal remodeling 
through actin polymerization and depolymerization (Artman et al., 2014; Brozovich et al., 2016).  
ȕ-actin is the predominant actin isoform required for cell migration (Artman et al., 2014). Actin 
polymerization occurs at the leading edge of the cell, known as lamelliopodia (Brozovich et al., 
2016), through the assembly of ATP-bound ȕ-actin monomers. This allows the cell to proceed 
towards the stimuli by extending its lamelliopodia frontwards and establishing new focal contact 
sites (Brozovich et al., 2016). The proximal end of the cell detaches from its original place 
through degrading the mature focal contact sites by metalloproteinases and calpain (Brozovich et 
al., 2016). Actin filaments depolymerize at the trailing edge as ATP hydrolyzes into ADP, which 
makes the actin monomers lose affinity and become more prone to breakage (Artman et al., 
2014). This drags the trailing end forward to the leading edge (Artman et al., 2014; Brozovich et 
al., 2016). ȕ-actin deficiency disrupts the actomyosin contractile function, actin polymerization, 
and creates persistent adhesive forces (Bunnell et al., 2011). This was demonstrated by our 
results. Plates treated with CL had no significant wound closure distance compared to non-
treated plates. This implies that VSMCs in the control plates were free to migrate compared to 
the treated plates, where VSMCs mobility was hindered. This could be an implication of ȕ-actin 
polymerization-deficiency due to calponin1 reduction. Unlike the dose-effect observed in 
calponin’s quantity when the tissues were treated with CL, there seem to be no CL dose-effect on 
VSMC migration. This could be because VSMC migration requires a threshold amount of 
calponin, and a reduction of this amount significantly ceases this cellular function. According to 
the literature, polymerization can be reversed in 150 seconds (Verlag, 2013), indicating that the 
effect caused by a disruption to the polymerization pathway is instantaneous. Our migration 
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results also potentially provide an explanation to the not significant increasing trend observed in 
MMP14 and calpain protein expressions. These proteins promote VSMC migration, and so their 
expression could have been upregulated to compensate for the hindered mobility. 
In addition to migration, ȕ-actin along with Ȗ-actin, another cytoplasmic actin, play a role in 
proliferation. Dedifferentiated VSMCs proliferate during vascular wall remodeling, as well as 
during atherosclerosis development. Proliferation proceeds through the cell cycle, and is 
finalized by cytokinesis. ȕ-actin activates RNA polymerase I gene transcription to support cell 
cycle progression and the proliferative state of cells. ȕ-actin also tethers nuclear myosin I and 
assembles RNA Polymerase I complex to rDNA genes (Almuzzaini et al., 2006). Nuclear 
myosin I motor, in turn, generates tension that stabilizes RNA polymerase I to rDNA during 
transcription (Almuzzaini et al., 2006). Thus, ȕ-actin is required for transcription during cell 
cycle. ȕ-actin deficiency abolishes rRNA levels and affects cell cycle progression and cell 
proliferation, which could explain the increase in multinucleated cells observed by Bunnell et al. 
in ȕ-actin mice knock-outs (Almuzzaini et al., 2006; Bunnell et al., 2011).  
Cytosolic actins are also localized in the mitotic spindle apparatus, centriolar region, and 
kinetochore, where actomyosin force accounts for chromosomal movement during mitosis, and 
for forming and closing the contractile ring during cytokinesis. Our results show that VSMC 
proliferation rate is unaffected by the addition of CL compared to the control sample. Even 
though we suggest that calponin1 reduction by CL affects ȕ-actin polymerization, which is 
involved in both migration and proliferation, we propose that the effect of CL on migration is 
more significant than on proliferation because ȕ-actin is the only actin involved in migration. In 
contrast, calponin1 has no effect on the cell-cycle functions performed by ȕ-actin monomers. 
Since calponin1 is involved in ȕ-actin polymerization, which is involved in cytokinesis and is 
potentially affected by ȕ-actin reduction, we propose that Ȗ-actin compensates for the loss of ȕ-
actin polymerization since Ȗ-actin polymerization is independent of calponin1. This provides an 
explanation to the observed normal cell division. 
We conclude that CL reduces calponin1 protein level, significantly restricting VSMC migration, 
but has no significant effect on VSMC proliferation or contraction. We also hypothesize that CL 
suppresses ȕ-actin polymerization, which is required for VSMC migration. To confirm this, ȕ-
actin polymerization should be tested. Ȗ-actin should also be quantified to understand whether it 
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compensates for the loss of ȕ-actin polymerization. The non-significant results with the observed 
trends should be tested by increasing CL dosages or increasing the incubation time. 
Contractibility experiments should be replicated more to increase reliability. Should there be any 
pattern observed in high-potassium or endotheline-1 contractions, these pathways will be 









Physiological Levels of Cardiolipin Acutely Affect 
Mitochondrial Respiration in Vascular Smooth 
Muscle Cells 








Cardiolipin (CL) is a phospholipid molecule found in the inner mitochondrial membrane. 
Normally, cardiolipin associates with and activates the mitochondrial respiratory complexes. CL 
also functions as a proton trap within the mitochondrial membranes. During myocardial 
infarction, CL gets released and becomes free to affect neighbouring cells. We previously 
showed that physiological concentrations of CL affect vascular epithelial cells migration and 
their involvement in angiogenesis, but no study was made on the effects of CL on vascular 
smooth muscle cells (VSMCs). VSMCs dedifferentiate and migrate during vascular injury and 
are key players in atherosclerosis development. Due to the central role that VSMCs play during 
atherogenesis and because CL is vital to cellular life, we hypothesize that abnormalities in CL 
concentrations may have significant implications on VSMC mitochondrial dysfunction and 
hence in cellular adaptations. In our study, we examined the acute effect of 1 µM and 10 µM CL 
on VSMC mitochondrial respiration using high-resolution respirometry technique in conjunction 
with the multiple substrate-uncoupler-inhibitor titration protocol. We found that CL significantly 
lowers VSMC respiration of complex I and complex III, which could potentially affect other 








Cardiolipin (CL) is a highly conserved (Mileykovskaya and Dowhan, 2009; Balasubramanian et 
al., 2015), unique phospholipid (Pangborn, 1942) molecule composed of four fatty acid side 
chains and three glycerol units found almost exclusively in the inner mitochondrial membrane 
(Schlame and Haldar, 1993; Hatch, 1998). Within these organelles, CL provides structural 
support (Gonzalvez and Gottlieb, 2007) and acts as a proton trap (Haines and Dencher, 2002) but 
has also been shown to promote mitophagy (Chu et al., 2013) by serving as an external signal for 
damaged mitochondria (Smith et al., 2011; Balasubramanian et al., 2015). CL is also involved in 
programmed cell death through anchoring of cytochrome c which, when released, triggers 
downstream apoptotic cascades (McMillin and Dowhan, 2002; Tuominen et al., 2002). 
Interestingly, CL is the only phospholipid molecule (De Windt et al., 1998; Paradies et al., 1999; 
Lesnefsky, 2001) that is significantly released during cardiomyocyte perforation after the 
myocardial infarction occurrence (Carnevale and Bergdahl, 2015), consequently affecting 
neighboring cells (Beauregard et al. 1980). 
Myocardial infarctions often originate from vascular occlusion involving the transition of the 
normally contractile vascular smooth muscle cells (VSMCs) to a synthetic, dedifferentiated 
phenotype, accompanied by characteristic changes in protein composition such as decreases in 
contractile filaments (Owens, 1995; Bergdahl et al., 2003; Majesky, 2007). This distinct 
plasticity is essential during the early stages of atherogenesis, and may confer a survival 
advantage as it provides means for the VSMCs to respond to altered conditions in its 
surroundings. Although a number of transcriptional networks that facilitate VSMC 
dedifferentiation have been mapped, the master regulators of smooth muscle cell phenotype shift 
remain elusive. There are no, or very few, studies describing the significance of CL in this 
process.  
CL is vital to cellular life and it is thus natural to imagine that this substance could also play an 
important role in cellular dedifferentiation and functions. Since CL is an important phospholipid 
located in the mitochondria and is essential in maintaining mitochondrial function, it is likely 
that abnormalities in CL concentration may have significant implications for mitochondrial 
dysfunction and hence in cellular adaptations.  
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The primary function of mitochondria is to produce ATP through the process of oxidative 
phosphorylation, conducted by complexes I–IV and the ATP synthase (complex V) (Duchen 
2004). This capacity relies heavily on substrate availability to produce energy as mitochondria 
utilize molecules derived from glucose and fatty acid oxidation. A key function of the 
mitochondria is to maintain the proton gradient created by the passage of electrons along the 
complexes (Duchen, 2004; Irwin et al., 2013). Energy stored by shunting these H+ to the outer 
membrane fuels ATP synthesis through complex V (Schultz and Chan, 2001; Irwin et al., 2013). 
In the normal situation, CL activates the respiratory complexes, as well as it functions as a proton 
trap within the mitochondrial membranes to concentrate the proton pool and to minimize the 
changes in pH in the mitochondrial intermembrane space (Carnevale and Bergdahl, 2015).  
Despite its seemingly central role in cellular function, little is known about CL’s effects on 
VSMC mitochondrial respiration. The aim of this study was thus to investigate whether 
physiological concentrations of CL downregulates mitochondrial respiration rates and ATP 
production. We hypothesize that an increase in CL concentration, in ranges normally seen 
following cardiac ischemia, will acutely reduce the oxidative phosphorylation in VSMCs from 
fresh aortic mouse tissue. 
Methods 
Animal Care 
Male C57Bl/6 mice, 7-8 months old were obtained from our Concordia University breeding 
colony and randomly assigned to either a control or two CL groups (1 µM and 10 µM). The mice 
were housed in a thermo-neutral environment (22°C), on a 12:12 h photoperiod, and were 
provided access to standard dry laboratory chow as well as water ad libitum. All procedures were 
approved by the Animal Ethics Committee of Concordia University (#30000259) and were 
conducted in accordance with guidelines of the Canadian Council on Animal Care.  
Experimental protocol 
The animals were euthanized by CO2 according to the approved animal ethics protocol after 
which the aorta was removed and immediately placed in an ice-cold buffer solution (BIOPS) 
containing (in mM): CaK2EGTA 2.77, K2EGTA 7.23, Na2ATP 5.77, MgCl2·6H2O 6.56, Taurine 
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20, Na2 Phosphocreatine 15, Imidazole 20, Dithiothreitol 0.5, MES 50, pH 7.1. The aortic 
samples were gently dissected, connective tissue and fat were removed before the vessels were 
separated using sharp forceps in ice-cold BIOPS buffer. Two aortas were used per condition, 
which provided approximately 6-8 µg of muscle tissue (wet weight) per sample. After dissection, 
the vessels were incubated in 2 ml BIOPS buffer containing 50 µg/ml saponin for 30 minutes. 
The aortas were then washed in ice-cold buffer (MiR05) for 2 x 10 min. MiR05 contains (in 
mM): EGTA 0.5, MgCl2·6H2O 3.0, K-lactonionate 60, Taurine 20, KH2PO4 10, HEPES 20, 
Sucrose 110, BSA 1g/l, pH 7.1. Measurements of oxygen consumption were performed at 37°C 
using high-resolution respirometry (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). 
The respirometric measurements were performed in the buffer MiR05 loaded in each chamber. 
This technique has been described in further detail elsewhere (Kuznetsov et al., 2008; Larsen et 
al., 2015). 
Mitochondrial respiratory measurements 
To avoid potential oxygen limitation, all experiments were carried out under hyperoxygenated 
conditions. 1 µM and 10 µM CL were added to each oxygraph chamber, which has a total 
volume of 2 ml. State 2 respiration (absence of adenylates) was assessed by addition of malate (2 
mM) and octanoyl carnitine (1.5 mM; ETFL), state 3 respiration was achieved by adding ADP (5 
mM; ETFP). This was followed by the addition of glutamate (10 mM; CIP) and succinate (10 
mM; CI+IIP), thus achieving maximal coupled respiration with convergent electron input to 
complex I and II of the electron transport system. Thereafter oligomycin (β μg/ml) was added to 
block complex V (LEAK) followed by antimycin A (β.5 μM) to inhibit complex III (ROX). 
Finally, ascorbate (β mM) and TMPD (500 μM) were added to measure COX activity. In this 
experiment, n = 5.  
Statistics 
Data are presented as means ± SE in all figures and tables. For all statistical evaluations, P<0.05 
was considered significant. One-way ANOVAs for the CL concentration factor was performed. 
Significant main effects or interactions were further analyzed by the Tukey post hoc test. The 
statistical analysis was performed using the software OriginPro 2015 (OriginLab Corporation, 




To investigate whether physiological concentrations of CL acutely affect VSMC mitochondrial 
respiration, we studied the oxygen consumption rates using high-resolution respirometry.  
As seen in Figure 8, there was a significant effect of CL after addition of the Complex I linked 
substrate malate (basal, ADP-restricted) at the p < 0.05 level for the conditions [F(2, 12) F = 
53.54, p = 0.00001]. A Tukey post-hoc test revealed significant differences between control and 
1 (p < 0.001) as well as control and 10 µM (p < 0.001) CL. 
 
Figure 8. Malate administration: Mitochondrial OXPHOS capacity per mg tissue measured in permeabilized 
muscle fibers as the concentration of CL increases after the addition of malate. The graph depicts a significant drop 
in mitochondrial respiration upon malate addition (p-value = 0.000) as the concentration of CL increased. The chart 
presents the average data of n = 5. Standard Error Mean measurements were used to calculate the error bars.  
Figure 9 demonstrates a significant effect of CL on lipid OXPHOS capacity induced by 
octanoylcarnitine at the p < 0.05 level [F(2, 12) F = 19.96, p = 0.0002] with a Tukey post-hoc 
test proving significant differences between control and 1 (p < 0.01) as well as control and 10 







Figure 9. Octanoylcarnitine administration: Mitochondrial OXPHOS capacity per mg tissue measured in 
permeabilized muscle fibers as the concentration of CL increases after the addition of octanoylcarnitine. The graph 
depicts a significant drop in mitochondrial respiration upon octanoylcarnitine addition (p-value = 0.000) as the 
concentration of CL increased. The chart presents the average data of n = 5. Standard Error Mean measurements 
were used to calculate the error bars. 
Further stimulating complex I respiration by the addition of glutamate, but now in an ADP-
stimulated environment, decreases significantly after addition of CL (Figure 10) [F(2, 12) F = 
9.55, p = 0.003]. Tukey post-hoc test revealed significant difference between control and 10 (p < 
0.05) as well as 1 and 10 µM (p < 0.01) CL.  
 
Figure 10. Glutamate administration: Mitochondrial OXPHOS capacity per mg tissue measured in permeabilized 
muscle fibers as the concentration of CL increases after the addition of glutamate in ADP-stimulated environment. 
The graph depicts a significant drop in mitochondrial respiration upon glutamate addition (p-value = 0.003) as the 
concentration of CL increased. The chart presents the average data of n = 5. Standard Error Mean measurements 







The change in respiration among the three samples after the addition of succinate and 
oligomycin, complex II and V specific substrates, was not significant, even though a decreasing 
pattern of respiration was observed (data not shown).  
The residual oxygen consumption (ROX) demonstrated by addition of antimycin, which inhibits 
complex III activity, was significantly downregulated after addition of CL as seen in Figure 11 
[F(2, 12) F = 13.56, p = 0.0008]. Using a post-hoc test (Tukey) it was determined that there was 
a significant difference between control and 10 (p < 0.01) as well as 1 and 10 µM (p < 0.001) 
CL. The addition of ascorbate + TMPD, which stimulates complex IV, revealed no significant 
difference (data not shown) in oxygen consumption between control and CL-treated samples. 
 
Figure 11. Antimycin administration (Residual Oxygen Consumption): Mitochondrial OXPHOS capacity per 
mg tissue measured in permeabilized muscle fibers as the concentration of CL increases after the addition of 
antimycin in the ADP-stimulated environment. The graph depicts a significant drop in mitochondrial respiration 
upon antimycin addition (p-value = 0.001) as the concentration of CL increased. The chart presents the average data 
of n = 5. Standard Error Mean measurements were used to calculate the error bars. 
Discussion 
CL has been shown to have pleiotropic roles in mitochondrial function including interactions 
with a number of inner mitochondrial membrane proteins, enzymes and metabolite carriers 
(Houtkooper et al., 2008; Paradies et al., 2009). This ubiquitous and intimate association 
between CL and energy-transducing membranes suggests an important role of CL in 
mitochondrial bioenergetics processes. Consequently, the ablation of CL causes abnormalities in 
mitochondrial structure and function, such as disorganized cristae and dissociated 





phosphorylation. An example of this is Barth syndrome, caused by a mutation in tafazzin, the 
enzyme responsible for CL remodeling. The biochemical consequences of tafazzin deficiency 
include a decrease in CL and an altered composition of CL molecular species (Schlame and Ren, 
2006). The clinical presentation of Barth syndrome includes cardiomyopathy, skeletal myopathy 
with muscle wasting and growth delay (Barth et al., 1983; Kelley et al., 1991).  
Hamsten et al. (1986) observed an increased number of patients with elevated anti-CL antibody 
levels in a group of young patients with myocardial infarction. This led us to study the acute 
effects of adding physiological concentrations of CL on VSMC mitochondria. CL is required for 
optimal activity of complex I-V (Fry and Green, 1981; Eble et al., 1990; Robinson, 1993). The 
currently favored view of the mitochondrial electron transport chain is the ‘random collision’ 
model, first proposed by Hackenbrock et al. (1986). According to this model, all components of 
the electron transport chain are distinct entities that can diffuse individually in the mitochondrial 
membrane. The electron transport depends on the random transient encounter of the four 
individual proteins of the complexes and the two small mobile electron carriers, CoQ and 
cytochrome c. CL seems to participate in the structural organization and stabilization of the 
respiratory chain complexes (Shägger, 2002). Such supercomplex organization of electron 
transport chain would likely increase the efficiency of electron/proton flux and hence, that of 
ATP synthesis, while also minimizing the generation of potentially toxic reactive oxygen 
species, that have been proposed to be involved in the pathogenesis of cardiovascular diseases. 
In our study, we examined the effect of 1 µM and 10 µM CL on VSMC mitochondrial 
respiration using high-resolution respirometry technique in conjunction with the multiple 
substrate-uncoupler-inhibitor titration protocol. This allowed us to understand the effect of CL 
on each complex.  
Our results indicate that CL significantly suppresses complex I mitochondrial respiration since 
oxygen consumption had significantly dropped in a dose-dependent manner as the concentration 
of CL increased after the addition of complex I inducer (Figure 8 and Figure 10).  
Since we used a sequential substrate addition protocol, we were able to quantify the change in 
respiration contributed by complex II. Because respiration in the three groups have increased 
approximately by the same amount upon the addition of complex II inducer (data not shown), we 
concluded that complex II activity was unaffected by CL addition.  
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To understand whether the drop in respiration is associated to glycolysis or ȕ-oxidation, we 
titrated a ȕ-oxidation inducer. The overall respiration of the samples increased approximately by 
the same amount, and the respiration ratio of lipid coupling was not significantly increased 
(comparing Figure 8 and Figure 9 data). This indicates that ȕ-oxidation was not disrupted by CL. 
CL associates with pyruvate transporters, which is produced during glycolysis (Chicco and 
Sparagna, 2006; Paradies et al., 2014). Thus, we hypothesize that a disruption in CL level 
impacts the function of the transporter into the mitochondria, consequently restricting energy 
production through glycolysis.  
When complex III was inhibited, respiration has significantly dropped, indicating that complex 
III is tightly associated with CL (Figure 11), while no significant drop in respiration was 
observed by complex IV and complex V. 
Previous histological studies demonstrated that CL associated to complexes I-V. However, our 
results indicate that acute addition of physiological concentrations of CL significantly impacts 
mitochondrial respiration, specifically complex I and III. We hypothesize that this could be due 
to the affinity or the proximity of CL’s binding to the proton channels. CL could also hinder 
binding of the citric acidic cycle coenzymes. CL has been shown to also associate with 
cytochrome c. Normally, cytochrome c functions as an electron shuttle between respiratory 
complexes III and IV in mitochondria. CL is proposed to disrupt this electron transfer function, 
which could lower cellular respiration.  
All in all, the drop of mitochondrial respiration due to CL, which is released upon myocardial 
infarction, could physiologically translate to lowering blood pump demand by the heart as 
oxygen required by cells decreases due to the decrease in their cellular demand. It has also been 
shown that when VSMCs were incubated with physiological concentrations of CL for 48 hours, 
the level of calponin significantly decreased (unpublished data). Calponin is a protein involved in 
VSMC migration through actin polymerization, which requires ATP. A drop in calponin lowered 
VSMC migration, and is proposed to lower actin polymerization rate, and thus the need for ATP 
drops. We hypothesize that VSMCs adjust to the drop in basal respiration by downregulating 
















The objective of this thesis was to understand the effects physiological concentrations of CL on 
VSMCs phenotypic switch, mitochondrial respiration, and functions, such as migration, 
proliferation, and contraction. We found that CL administration significantly affected the overall 
mitochondrial respiration rate, specifically complex I and III. CL also significantly affected only 
calponin out of the other tested markers, suggesting that CL has a specific effect on calponin. 
Because CL did not affect other dedifferentiation markers, we suggest that it is unlikely that CL 
stimulates VSMC dedifferentiation.  
Because CL is associated with α- actin polymerization, which is involved in aortic contraction, 
and ȕ-actin polymerization, which is involved in migration and proliferation. This led us to 
explore the effect of CL on these functions, and found that contraction, which is α- actin 
dependent, was unaffected by calponin reduction, proposing a potential protein that could be 
involved in α- actin polymerization. We found a significant restriction in VSMC migration upon 
the administration of CL. Since ȕ-actin is the only actin involved in migration, we proposed that 
ȕ-actin polymerization could be affected by calponin’s drop, which in turn impairs VSMC 
mobility. In contrast, we proposed that CL administration would not have a significant impact on 
VSMC proliferation since ȕ-actin is not the only actin involved in proliferation, and that Ȗ-actin 
could compensate for its function. Our data indeed demonstrates that addition of physiological 
concentrations of CL has no significant effect on VSMC proliferation.  
All in all, because VSMC migration determines the beginning of the irreversible stages in 
atherosclerosis development, CL is proposed to potentially arrest atherosclerosis development as 
it restricts VSMC migration. Moreover, cardiolipin lowered VSMC mitochondrial respiration, 
which physiologically could translate to lowering blood pump demand by the heart as the oxygen 
demand by cells decreases after a myocardial infarction. Thus, we hypothesize that CL could act 
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What is Cardiolipin? 
Cardiolipin (CL) is a phospholipid that was isolated in 1942 by Mary Pangborn from bovine 
cardiac muscle, from which CL derived its name (Chicco and Sparagna, 2006; Houtkooper and 
Vaz, 2008). CL has a diphosphatidylglycerol head, which accounts for two phosphates and three 
glycerol molecules (Haines and Dencher, 2002; Zhong et al., 2014). Unlike most phospholipids, 
CL has four fatty acyl chains that hydrophobically interact with each others (Lewis and 
Mcelhaney 2009). The presence of four fatty acyl chains is primordially preserved, and account 
for CL’s conical structure and phase behavior (Zhong et al., 2014; Balasubramanian et al., 2015; 
Kooijman et al., 2017). CL forms a bilayer with negative membrane curvature (Ren et al., 2014) 
at physiological pH, while it forms a hexagonal HII phase arrangement at pH lower than ≈β.8 
(Ren et al., 2014; Kooijman et al., 2017). 
There is controversy to whether CL carries one or two negative charges. CL is said to have a PK1 
value below 4.0, and PK2 value above 8.0 (Haines and Dencher, 2002). When the first phosphate 
group is deprotonated, the free hydroxyl group of the central glycerol molecule forms a hydrogen 
bond with the oxygen atom of the other phosphate groups, stabilizing the molecule (Haines and 
Dencher, 2002). This results in a higher PK2 value, and implies that CL has one negative charge 
at physiological pH (Haines and Dencher, 2002; Kooijman et al., 2017). This notion has been 
challenged. Recent studies show that both CL PK values are ≈β.5, meaning that the phosphate 
groups give CL two negative charges at physiological pH (Tyurina et al., 2006; Paradies et al., 
2014; Kooijman et al., 2017).  
Cardiolipin biosynthesis 
In eukaryotic cells, CL resides in the inner mitochondrial membrane (Chicco and Sparagna, 
2006; Zhong et al., 2014). It makes up 10-20% of the phospholipids present in the mitochondrial 
inner membrane, and is the only phospholipid that is synthesized there (Haines and Dencher, 
2002; Paradies et al., 2014). CL is biosynthesized in four steps in the inner mitochondrial 
membrane inner leaflet (Chicco and Sparagna, 2006; Paradies et al., 2014).  
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On the outer leaflet of the mitochondrial outer membrane, phosphatidic acid is made 
(Chakraborty et al., 1999), which is the first precursor involved in CL biosynthesis (Ren et al., 
2014). Since CL is biosynthesized in the inner leaflet of the inner mitochondrial membrane, 
phosphatidic acid has to be transported across the membranes (Ren et al., 2014). This 
transportation is mediated by Ups1 (in yeast) (Connerth et al., 2012). 
In the mitochondrial inner membrane, phosphatidic acid is condensed with CTP (Cytidine 
triphosphate Tam41 in yeast) (Petit et al., 1994), mediated by CDS (CDP-DG synthase) (Tamura 
et al., 2010), to form cytidinediphosphate-diacylglycerol (CDP-DAG). PGP synthase (PGPS 
Pgs1 in yeast) (Chang et al., 1998) mediates the conversion of CDP-DAG to PG-P 
(Phosphatidylglycerol-phosphate) (Ren et al., 2014). PGPP (PGP phosphatase; Gep4 in fungi 
(including yeast) and some plants (Osman et al., 2010), and PTPMT1 in mammals) (Zhang et al., 
2011) dephosphorylates PG-P into PG (Phosphatidylglycerol) (Chicco and Sparagna, 2006; Ren 
et al., 2014). Finally, CL is assembles by condensing phosphatidylglycerol and 
cytidinediphosphate-diacylglycerol molecules, mediated by CL synthase (Crd1 in yeast) (Jiang et 
al., 1997; Chang et al., 1998; Tuller et al., 1998; Chicco and Sparagna, 2006).  
This biosynthesis process yields asymmetrical and saturated immature CL that is variable in 
length (Chicco and Sparagna, 2006). The final, mature CL structure is achieved though 
remodeling process, which is not yet completely understood, forming a homogeneous and 
unsaturated mature molecule (Chicco and Sparagna, 2006; Claypool and Koehler, 2012).  
Cardiolipin remodeling 
CL fatty acyl chain composition vary among organisms and tissues to fit to their biological 
needs, even though little is known about the variable CL species (Chicco and Sparagna, 2006; 
Claypool and Koehler, 2012). In eukaryotes, CL mostly consists of linoleic acid (18:2) acyl 
chains, suggesting the biological significance of the 18:2 CL across species (Chicco and 
Sparagna, 2006; Zhong et al., 2014). The 18:2 CL also makes up 70-95% of CL found in a 
healthy mammalian heart (Lesnefsky et al., 2001; Chicco and Sparagna, 2006; Zhong et al., 
2014). To generate functional-specific, symmetrical, mature CL species, the CL remodeling 
process is needed, which is incompletely understood (Claypool and Koehler, 2012). It remains 
unclear whether CL remodeling process also repairs damaged CL molecules (Claypool and 
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Koehler, 2012). It has been argued that CL remodeling occurs exclusively to newly synthesized 
CL molecules, and so cannot be involved in fixing damaged CL (Xu and Schlame, 2014), which 
other studies has supported that it can fix oxidatively damaged CL (Claypool and Koehler, 
2012). 
The remodeling process starts by deacylating a fatty acyl chain from the nascent, immature CL 
through phospholipases (Cld1p in yeast, iPLAβȖ in mammals), which is activated by reactive 
oxygen species (ROS) (Chicco and Sparagna, 2006; Claypool and Koehler, 2012; Ren et al., 
2014). This forms a monolysocardiolipin molecule, which is a CL with three acyl chains 
(Claypool and Koehler, 2012). A deletion in the Cld1p-coding gene disrupts CL remodeling, 
altering the CL-acyl composition and favoring saturated fatty acyl chains over the 18:2 
composition (Beranek et al., 2009; Claypool and Koehler, 2012). iPLAβȖ mutations reduce total 
CL content and disrupts its molecular structure (Claypool and Koehler, 2012). iPLAβȖ-mutated 
mice experience a compromised cold-tolerance ability, and reduced bioenergetics functions 
(Claypool and Koehler, 2012). iPLAβȖ deletions do not display the complete loss-of-CL, lethal 
phenotype observed in PGPP deletions (Claypool and Koehler, 2012). iPLAβȖ-deleted mice had 
healthy and mature CL molecules, suggesting that iPLAβȖ may not be the only enzyme 
responsible for the remodeling-initiation in mammals (Claypool and Koehler, 2012). This 
indicates that iPLAβȖ is not a Cld1p ortholog, and that its function is complemented by another 
enzyme (Ren et al., 2013).  
Other phospholipases can also deacylate CL into monolysocardiolipin. These include, iPLA1ȕ, 
iPLA1Ȗ, and cPLAβ (Ren et al., 2014). iPLA1ȕ (found in mice, drosophila, and humans) resides 
in the mitochondria (Gadd et al., 2006; Seleznev et al., 2006; Malhotra et al., 2009). iPLA1ȕ 
depletes CL and increases monolysocardiolipin levels in the absence of re-acylation enzymes, 
confirming its deacylating role in CL (Malhotra et al., 2009; Hsu et al., 2013). iPLA1ȕ is also 
associated with repairing peroxidized CL and inhibiting apoptosis (Seleznev et al., 2006; Zhao et 
al., 2010). This further supports the role of iPLA1ȕ in CL remodeling and maturation. iPLA1Ȗ is 
another phospholipase found in mitochondria and peroxisomes (Ren et al., 2014). iPLA1Ȗ –
diminished hippocampi is associated with decreased monolysocardiolipin levels, and increased 
immature CL levels (Mancuso et al., 2009; Zachman et al., 2010). This confirms its role as a CL 
deacylator. Cytosolic PLA2 (cPLA2) hydrolyzes CL present on the mitochondrial surface 
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(Buckland et al., 1998; Hsu et al., 2013; Ren et al., 2014). This regulates externalized-CL, and 
could act as a defense mechanism against mitophagy and apoptosis (explained later).  
Following CL hydrolysis, CL is reacylated by reattaching a fatty acyl chain to the 
monolysocardiolipin molecule, restoring the tetra-acyl chain structure of CL (Claypool and 
Koehler, 2012). Re-acylation can be performed by three different enzymes, collectively referred 
to as monolysocardiolipin remodelers. These include: Tafazzin, monolysocardiolipin 
acyltransferase 1 (MLCLAT1), and acyl-CoA:lysocardiolipin acyltransferase-1 (ALCAT1), the 
first being the most understood. These remodeler enzymes are located in distinct sites, but it 
remains unknown whether these monolysocardiolipin remodelers are CL-species or -location 
specific (Claypool and Koehler, 2012).   
Tafazzin is an integral transcyclase, present in both mammals and yeast (Xu et al., 2006; 
Claypool and Koehler, 2012). It is located in the inner and the outer mitochondrial membranes in 
the leaflets facing the intermembrane space (Claypool and Koehler, 2012). Tafazzin finalizes CL 
remodeling by non-specifically translocating a fatty acyl chain from a neighboring phospholipid 
molecule to the monolysocardiolipin, until a stable, homogeneous CL is formed (Claypool and 
Koehler, 2012). This is challenged by a series of experiments demonstrating that tafazzin has 
high acyl-specificity transfer that is based on the lipid phase state and properties (Schlame et al., 
2012). Tafazzin is argued to mediate the de-attachment and re-attachment of acyl chains 
needlessly of phosphlipases (Ren et al., 2014). 
MLCLAT1 is another monolysocardiolipin remodelers found in mammalian mitochondria in the 
matrix-facing leaflet of the inner membrane (Claypool and Koehler, 2012). MLCLAT1 has acyl 
chain and lysolipid specificity required to attain a mature, tetralineoyl-CL (Claypool and 
Koehler, 2012). MLCLAT1-knockout HeLa cells have reduced linoleate CL molecules, while its 
upregulation increased the linoleate content in cardiolipin (Claypool and Koehler, 2012). 
ALCAT1 is present in mammals, and is localized in the mitochondria associated membranes of 
the endoplasmic reticulum (Claypool and Koehler, 2012). ALCAT1 reacylates 
monolysocardiolipin with CoA-bound long, unsaturated acyl chains (Claypool and Koehler, 
2012). Upregulated ALCAT1 gene has decreased mature and total CL pool (Claypool and 
Koehler, 2012). This causes proton leakage, which disrupting mitochondrial respiration and the 
mitochondrial inner membrane potential (Claypool and Koehler, 2012). ALCAT1 
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overexpression also impaired mitochondrial fusion mechanism, in which CL plays an essential 
role. It increased ROS production and polyunsaturated-containing CL levels that are associated 
with mitochondrial dysfunction and mtDNA instability (Claypool and Koehler, 2012). ALCAT1 
knockdown rodents had increased linoleate, mature CL and the total CL pool (Claypool and 
Koehler, 2012). This suggests that, unlike tafazzin and MLCLAT1, ALCAT1 acylates 
monolysocardiolipin to impair CL molecules (Claypool and Koehler, 2012). The relevance of 
this remains unknown, but it is possible that ALCAT1 promotes apoptosis when CL is 
externalized.  
Cardiolipin Translocation and Release 
CL biosynthesis requires phosphatidic acid translocation from the outer to the inner membrane. 
CL translocation from the inner to the outer mitochondrial membrane is needed to relocate 
remodeled CL, and to mediate cellular processes like mitophagy or apoptosis, depending on the 
degree of the mitochondrial damage (Heit et al., 2011; Chu et al., 2013). Several translocating 
proteins have been identified, even though CL translocation mechanisms between and within 
membranes remain unclear (Connerth et al., 2012; Ren et al., 2014). 
Intramembrane translocation 
ADP/ATP carriers 
Intramembrane translocation of CL from one leaflet to the other in the inner membrane remains 
unclear (Ren et al., 2014). It has been proposed that CL might flip from one leaflet to the other 
by interacting with integral proteins such as the ADP/ATP carriers as it is the most abundant 
protein carrier within the mitochondrial inner membrane (Klingenberg, 2009; Ren et al., 2014).   
Intermembrane translocation: 
UPS1 
Ups1 is a conserved intermembrane space protein found in yeast (Connerth et al., 2012). During 
the early stages of CL biosynthesis, Ups1 shuttles phosphatidic acid from the outer mitochondrial 
membrane to the inner mitochondrial membrane via a lysosome, but cannot translocate CL or 
other negatively charged phospholipids (Connerth et al., 2012). Phosphatidic acid-bound Ups1 
interacts with a stabilizing protein called Mdm35. This Ups1-Mdm35 complex recognizes 
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negatively charged phospholipids on the recipient membranes, which triggers Ups1-Mdm35 
dissociation, releasing phosphatidic acid into the recipient, inner membrane, where CL 
biosynthesis takes place (Connerth et al., 2012; Ren et al., 2014). 
Pro-mitophagy stimuli 
Pro-mitophagy stimuli, including: rotenone, 6-hydroxydopamine, and staurosporine, trigger CL 
externalization from the inner mitochondrial membrane to the outer mitochondrial membrane in 
SH-SY5Y cell-line and in primary cortical neurons (Chu et al, 2013).  
MINOS/MICOS/MitOS 
MINOS/MICOS/MitOS is a large hetero-oligomeric protein complex and is also known to 
connect the inner mitochondrial membrane to the outer mitochondrial membrane (van der Laan 
et al., 2012), and to bind CL (Hoppins et al., 2011; Weber et al., 2013; Ren et al., 2014). 
Mutations in this complex did not affect the distribution of phospholipids in the mitochondrial 
membrane (Harner et al., 2011), so it remains unclear whether the complex is involved in CL 
translocation (Ren et al., 2014).  
ATAD3 
ATPase family AAA domain-containing protein 3 (ATAD3) is an ATPase-bound protein family 
that is also present at the inner-outer membrane contact sites (Li and Rousseau, 2012) and so is 
important to sustain the mitochondrial network (Hoffmann et al., 2009; Gilquin et al., 2010). 
ATAD3 is involved in cholesterol transfer (Gilquin et al., 2010; Issop et al., 2013), but it 
remains unclear whether this protein translocates CL (Connerth et al., 2012; Ren et al., 2014).  
ATP8B1 
ATP8B1 is a CL pump protein conserved in humans, mice, and rats, and is present in apical 
epithelial membranes (Ray et al., 2010). Atp8b1 binds and translocates CL from the outer to the 
inner leaflet of membrane bilayers and is important for maintain a healthy alveolar surfactant in 
the lungs (Ray et al., 2010). Atp8b1 mutations result in increased CL concentrations in the lung’s 
fluid, which promotes pneumonia (Ray et al., 2010). This signifies the important role of Atp9b1 
as a CL transporter.  
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NDPK-D and MtCK 
Nucleoside diphosphate kinase D (NDPK-D) and mitochondrial creatine kinases (MtCK) are 
kinases that physically link the inner and the outer mitochondrial membranes together (Eder et 
al., 2000; Schlattner and Wallimann, 2000; Tokarska-Schlattner et al., 2008; Schlattner et al., 
2009; Ren et al., 2014). These two kinases have high affinity to CL, and promote lipid 
intermembrane transfer (Epand et al., 2007). Overexpression of either NDPK-D or MtCK 
kinases have increased CL content in the outer mitochondrial membrane, indicating that NDPK-
D and MtCK are involved in CL transfer from the inner to the outer membrane, and that they are 
complementary to one another (Lacombe et al., 2009; Schlattner et al., 2009; Schlattner et al., 
2013). 
PLS3  
Phospholipid scramblase-3 (PLS3) is a mitochondrial enzyme found in mammals (Chu et al, 
2013; Inuzuka et al., 2013), and is linked to cell signaling, injury, and apoptosis (Liu et al., 2003; 
Gonzalvez and Gottlieb, 2007; Sahu et al., 2007; Van et al., 2007; Bevers and Williamson, 2010; 
Chu et al, 2013). PLS3 is involved in CL translocation from the inner mitochondrial membrane 
to the outer mitochondrial membrane (Liu et al., 2003; Van et al., 2007; Chu et al., 2013), even 
though it is not the actual vehicle that translocates CL (Ren et al., 2014). Instead, integral outer 
proteins that bind CL are thought to directly translocate CL. These proteins include the Bcl-2 
family or VDAC (Rostovtseva and Bezrukov, 2008; Raemy and Martinou, 2014).   
CL translocation beyond mitochondria 
CL has been detected in peroxisomes and the plasma membrane, indicating that CL is 
translocated from the mitochondrial surface to other organelles (Zinser et al., 1991; Sorice et al., 
2000; Sorice et al., 2004; Wriessnegger et al., 2007; Ren et al., 2014). It has been shown that 
mitochondria-derived vesicles mediate CL translocation from mitochondria to peroxisomes 
(Neuspiel et al., 2008). 
Myocardial impairments 
CL loss appear to exceed the loss of other phospholipids from cardiomyocytes during myocardial 
ischemia or myocardial infarction (Chicco and Sparagna, 2006). During these myocardial 
defects, it also appeared that CL was selectively lost from the subsarcolemmal mitochondria, 
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which are located beneath the interfibrillar and plasma membrane, but not from the interfibers’ 
(Rossen et al., 1994)), which are located between myofibrils (Lesnefsky et al., 2001; Chicco and 
Sparagna, 2006). Myocardial infarction and ischemia trigger sarcolemma tear, necrosis, and 
apoptosis, all of which releases various intracellular components, including CL-positive 
membrane fragments (Carnevale and Bergdahl, 2015). Released CL can affect neighboring cells, 
and is marked by an elevation in anti-CL antibodies, which recognizes peroxidized CL, in 
patients’ bodies (Zhong et al., 2014). Cells were also found to release CL-containing 
mitochondrial fragments in different pathologies, such as: stress, acute trauma, necrosis, and 
neutrophil activation (Hamsten et al. (1986; Balasubramanian et al., 2015).  
Cardiolipin regulation 
Regulating CL Biosynthesis  
The amount of CL present in mitochondria inner membrane is regulated (Connerth et al., 2012). 
When CL and/or phosphatidylglycerol are present in high physiological concentrations, they 
impair the Ups1-Mdm35 dissociation mechanism that releases phosphatidic acid to the recipient 
membrane. This prevents excessive CL biosynthesis and accumulation (Connerth et al., 2012). 
Limiting CL externalization 
MitoPLD is a mitochondrial phospholipase D molecule that resides on the mitochondrial outer 
membrane. MitoPLD degrades CL into phosphatidic acid, regulating the amount of CL exiting 
the mitochondria (Claypool and Koehler, 2012). This prevents provoking an autoimmune 
response, as CL release has been shown to provoke of anti-CL antibodies (Claypool and Koehler, 
2012). It could also be a regulatory mechanism to inhibit apoptosis and mitophagy. 
Roles of Cardiolipin 
CL is involved in various cellular processes, such as: immunity, mitophagy, apoptosis, supports 




Immunity (Bacterial defense mechanism) 
CL is externalized and co-presented with Toll-like receptor 4 and lipopolysaccharide in gram 
negative bacteria when invading a host (Balasubramanian et al., 2015). This inhibits the host’s 
ability to respond to the bacterial Toll-like receptor and produce cytokines against it 
(Balasubramanian et al., 2015). Thus, CL acts as a bacterial defense mechanism 
(Balasubramanian et al., 2015). Fortunately, since CD36 is not involved in this protection 
mechanism, the host macrophages can fight these invasive bacteria through their CD36-
dependant mechanism (Balasubramanian et al., 2015).   
Immunity (Macrophage-dependent cell death) 
Macrophages recognize and engulf apoptotic cells that display the universal, extracellular, self-
destruction signal, aminophospholipid phosphatidylserine (Balasubramanian et al., 2015). 
Aminophospholipid phosphatidylserine is found on the membranes of organelles and cells 
(Balasubramanian et al., 2015). This signal is absent from mitochondrial membrane due to the 
presence of phosphatidylserine decarboxylase, which degrades aminophospholipid 
phosphatidylserine (Balasubramanian et al., 2015). To overcome this, mitochondrial membrane 
uses CL as a macrophage-degradation signals (Claypool and Koehler, 2012; Balasubramanian et 
al., 2015). 
Intracellularly, CL can trigger mitophagy when displayed on the surface of damaged 
mitochondria (explained later) (Balasubramanian et al., 2015). Extracellularly, CL is 
externalized and sometimes released along with mitochondrial fragments from cells that have 
experienced trauma or other pathophysiologies (Balasubramanian et al., 2015). Externalized CL 
are then recognized by the macrophages’ surface CDγ6 receptors, triggering the engulfment of 
the CL-presenting cell (Balasubramanian et al., 2015). CD1 receptors of antigen-presenting cells 
can also bind to CL and present it to immune effector cells, such as the T cells (Claypool and 
Koehler, 2012). These indicate that CL could either be secreted on the cell’s surface through 
secretory pathways, or that an autophagosome have degraded a mitochondria and then presented 
it to an antigen-presenting cell (Claypool and Koehler, 2012). Under normal conditions, 
externalized mitochondrial CL is exposed to CD1 in scarce amounts below the threshold that 
triggers an immune reaction (Claypool and Koehler, 2012). 
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The notion that CL is recognized by the immune system is further supported by the increased 
levels of anti-cardiolipin antibodies in patients with anti-phospholipid syndrome (Claypool and 
Koehler, 2012). Whether these anti-cardiolipin antibodies are produced against mitochondrial CL 
or pathogenic CL remains unclear (Claypool and Koehler, 2012).  
External CL destruction signals seem to be fulfilling the same role as the external 
aminophospholipid phosphatidylserine signal, but the mechanisms by which each triggers self-
clearance are remarkably different (Balasubramanian et al., 2015). CL’s function as an internal 
mitochondrial self-destruction signal predominates its function as an extracellular signal, as 
aminophospholipid phosphatidylserine is the main externalized signal for self-destruction 
(Balasubramanian et al., 2015).   
Mitophagy 
Mitochondria is a fundamental organelle in eukaryotic cells (Zhong et al., 2014). Mitochondrial 
respiration generates some ROS, whereas mitochondrial dysfunction overproduces it (Zhong et 
al., 2014). ROS signals for automated cell death, and so is associated with neurodegenerative 
diseases, aging, and other pathologies (Chu et al, 2013; Zhong et al., 2014). To avoid this, 
eukaryotic cells have established a process to degrade the defected mitochondria in order to 
preserve the cell’s viability (Zhong et al., 2014). This process is known as mitophagy, which 
remains incompletely understood (Chu et al, 2013; Zhong et al., 2014).  
In cortical neurons and SH-SY5Y cell line, an essential provoker of mitophagy is externalized 
CL from the mitochondrial inner membrane to the mitochondrial outer membrane (Chu et al, 
2013). Different cells have different thresholds of externalized CL to induce mitophagy, but they 
seem to agree in the concept (Chu et al, 2013). CL externalization is stimulated as a response to 
several pro-mitophagy factors, such as: rotenone, 6-hydroxydopamine, and staurosporine (Chu et 
al, 2013). These cause CL translocation from the inner mitochondrial membrane to the outer 
mitochondrial membrane via PLS3 (Chu et al, 2013). CL externalization is compromised upon 
PLS3 deletion, regardless of the rotenone level (Chu et al, 2013). 
Upon CL externalization, CL binds and is recognized by autophagosomes through microtubule-
associated-protein-1 light chain 3 (LC3) (Chu et al, 2013). LC3 is an autophagy protein that 
covalently bridges CL-containing cargo to the autophagosome, mediating mitophagy (Chu et al, 
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2013).  Rotenone was found to increase the presence and the mitochondrial co-localization of 
LC3 (Chu et al, 2013). The cortical rotenone treatment had increased the percentage of only CL 
(but not other phospholipids) in the mitochondrial outer membrane by ten-folds, relative to the 
external CL basal amount, 0.8%. This shows that CL is being externalized (Chu et al, 2013).  
In contrast to the well-studied lipids that becomes oxidized upon apoptosis, CL molecules were 
not peroxidized upon mitophagy, suggesting mitophagy occurs to prevent the accumulation of 
pro-apoptotic signals, even though this notion was rejected by some studies (Chu et al, 2013; 
Zhong et al., 2014).  
Apoptosis  
In contrast to mitophagy, whose occurrence is debated on whether CL gets peroxidizes, ROS 
oxidizes polyunsaturated CL acyl chains during apoptosis (Paradies et al., 2014; Zhong et al., 
2014). CL oxidation is related to mitochondrial dysfunction, apoptosis regulation, and several 
pathologies (Zhong et al., 2014). Here we discuss CL-triggered apoptosis, and CL’s link to 
cytochrome c, a positively charged molecule (Kooijman et al., 2017). Cytochrome c is a 
mitochondrial protein involved in electron transfer from complex III to complex IV in the 
electron transport chain (Paradies et al., 2014; Ren et al., 2014;). Cytochrome c plays an 
instrumental role in triggering apoptosis when it binds to CL (Chicco and Sparagna, 2006; 
Paradies et al., 2014).  
CL primarily resides in the inner leaflet of the mitochondrial inner membrane, but is peroxidized 
and translocated to the outer leaflet upon mitochondrial injuries and ROS production (Belikova 
et al., 2009; Paradies et al., 2014). The mechanism for this and the relevance remains unclear 
(Gonzalvez and Gottlieb, 2007; Ren et al., 2014; Paradies et al., 2014). In the outer leaflet, CL 
binds to cytochrome c (Ren et al., 2014), which is a dormant peroxidase (Kooijman et al., 2017). 
Cytochrome c is anchored to the inner membrane through two CL binding sites, the A-site and 
the C-site (Paradies et al., 2014). The A-site binds to CL through electrostatic interactions 
(Chicco and Sparagna, 2006; Kapralov et al., 2007; Muenzner et al., 2013; Paradies et al., 2014), 
while the C-site binds to CL through hydrogen and hydrophobic interactions (Paradies et al., 
2014). The latter induces partial unfolding of cytochrome Met-80 residue with its associated 
heme-iron (Paradies et al., 2014). 
80 
 
Peroxidized CL introduces conformational changes in cytochrome c and destabilize the tertiary 
structure of its heme group (Paradies et al., 2014; Ren et al., 2014; Kooijman et al., 2017). This 
CL-cytochrome c complex becomes an activated pro-apoptotic peroxidase complex (Kooijman et 
al., 2017), which further oxidizes CL (Kagan et al., 2005; Paradies et al., 2014; Ren et al., 2014). 
Oxidized CL in turn enhances the oxidation ability of the peroxidase, which further oxidizes 
polyunsaturated in a continuous positive-feedback loop (Kagan et al., 2005; Tyurina et al., 2006; 
Paradies et al., 2014; Ren et al., 2014). The unfolded cytochrome c escapes to the cytosol, where 
it activates cellular pathways that orchestrates apoptosis (Kagan et al., 2005; Chicco and 
Sparagna, 2006; Paradies et al., 2014). The release of cytochrome c to the cytosol has been 
linked to permeablizing the mitochondrial membrane, which facilitates the release of the 
apoptotic factors from the mitochondria, but this remains unclear (Belikova et al., 2007; Paradies 
et al., 2009; Paradies et al., 2014; Raemy and Martinou, 2014). 
The oxidation reaction of CL with cytochrome c produces hydroperoxy octadecadienoic acid-CL 
(HpODE-CL), which gets reduced, forming hydroxyoctadienoic acid (HODE-CL) and keto-
octadecadienoic acid (KODE-CL) (Zhong et al., 2014). Further intra-molecular reactions occur, 
in vivo and in vitro, to form other reactive, electrophilic aldehyde species such as, epoxyalcohol-
aldehyde-CL (EAA-CL), 4-Hydroxy-2-nonenal (4- HNE), and 4-oxo-2-nonenal (4-ONE) – the 
mechanisms by which these molecules are formed remain ununderstood (Zhong et al., 2014). 
These electrophilic molecules covalently modify the structure of nucleophilic segments in a 
protein, which changes the function of the protein (Zhong et al., 2014). EAA-CL can only target 
proteins at the local environment of its generation, whereas 4- HNE and 4-ONE can diffuse and 
affect proteins that are further from these molecules’ generation site (Zhong et al., 2014). The 
involvement of these molecules in apoptosis remains unknown (Zhong et al., 2014).  
4-HNE has been associated to cell death and was found in atherosclerotic mice (Zhong et al., 
2014). It is known that 4-HNE suppresses contractile function, while it enhances ROS 
production. 4-HNE is also known to be involved in atherosclerotic pathways and in other 
cardiovascular diseases (Zhong et al., 2014). In cases of endothelial dysfunction and 
atherosclerosis, anti-oxidized CL antibodies are released (Zhong et al., 2014). These antibodies 
are thought to have been formed as a result of the covalent modifications caused by the lipid 
electrophiles (Zhong et al., 2014).  
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Several strategies have been studied to inhibit CL oxidation, which relates to atherosclerosis and 
other diseases (Zhong et al., 2014). Inhibiting the cytochrome c-CL peroxide complex inhibited 
apoptosis, and overexpressing lipid-reducing factor have lowered liver apoptosis, cytochrome c 
release, and CL oxidation (Zhong et al., 2014). Acet-aminophen (ApAP) is a peroxidase 
inhibitor. It has been shown that ApAP inhibit the formation of peroxidized CL and its by-
products (EAA-CL and HODE-CL) in dose-dependent manner (Zhong et al., 2014). Recent 
studies show that ApAP protects the kidney against oxidative damage (Zhong et al., 2014).   
In addition to the role of CL in apoptosis through cytochrome c, CL is also involved in other 
pathways that lead to apoptosis (Paradies et al., 2014). CL on the outer mitochondrial membrane 
anchors and activates recruited caspase-8 proteins (Paradies et al., 2014). Caspase-8 activation 
truncates Bid protein, which belongs to the pro-apoptotic Bcl-2 family, into t-Bid (Gonzalvez 
and Gottlieb, 2007; Paradies et al., 2014). t-Bid is then translocated to the outer mitochondrial 
membrane, where it allows the binding of Bax oligomers, another pro-apoptotic protein that 
promotes mitochondrial outer membrane permeablization (Gonzalvez and Gottlieb, 2007; 
Paradies et al., 2014). t-Bid also interacts with mitochondria to remodels the cristae and further 
promote cytochrome c release, stimulating mitochondrial fragmentation and apoptosis 
(Gonzalvez and Gottlieb, 2007; Paradies et al., 2014).  
It has been shown that under the sub-lethal threshold, ROS levels are enough to trigger CL 
translocation, but not CL peroxidation – a characteristic observed in mitophagy, despite the 
debate (Chu et al., 2013). Thus, unoxidized CL is translocated from the inner to the outer leaflet 
of the mitochondrial inner membrane, rather than oxidized CL (Chu et al., 2013; Ren et al., 
2014). Through this, mitophagy was initiate, but not apoptosis in sub-lethal mitochondrial 
injuries, preserving the cell’s viability (Chu et al., 2013; Ren et al., 2014).  
Supports cristae 
The four fatty acyl chains of CL accounts form its conical structure and phase behavior (Zhong 
et al., 2014; Kooijman et al., 2017). CL forms a bilayer with negative membrane curvature at 
physiological pH, while it forms a hexagonal HII phase arrangement (Ren et al., 2014; Kooijman 
et al., 2017) at pH lower than ≈β.8 or at NaCl concentrations above 1.6 M at a neutral pH 
(Kooijman et al., 2017). These critical values depend on the length and saturation levels of the 
specific CL acyl chains; for example, long, unsaturated CL can switch from bilayer lamellar to 
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the HII phase at NaCl concentrations around 1-3 M, while short, saturated CL exhibit bilayer to 
HII phase switch at NaCl concentrations close to 6 M (Lewis and Mcelhaney, 2009).  
The HII phase structure of CL induces a negative curvature strain, which promotes membrane 
bending – an important feature of the cristae (Jouhet, 2013). These bents also form the contact 
sites between the inner and the outer mitochondrial membrane (Jouhet, 2013). HII phase 
structure is also involved in the sarcoplasmic calcium pumps and in other enzymes’ activities and 
anchoring (Jouhet, 2013). This structure also promotes for membrane stalk formation, regulating 
membrane fusion and fission (Jouhet, 2013).  
CL & bioenergetics (Stabilize enzymes and respiratory chain complexes) 
CL is negatively charged and have long hydrophobic tail, allowing it to form strong ionic and 
hydrophobic interactions with neighboring molecules (Lewis and Mcelhaney 2009; Paradies et 
al., 2014; Ren et al., 2014). CL tightly binds to the CL-affinity sites on the mitochondrial 
respiratory complexes, I-V, via hydrophobic and ionic bonds (Eble et al., 1989; Lesnefsky et al., 
2001; Paradies et al., 2014). 
Complex I, also known as NADH-ubiquinone oxidoreductase, is involved in electron transport 
from NADH to ubiquinone (Paradies et al., 2014). Complex I associates with CL (Chicco and 
Sparagna, 2006; Paradies et al., 2014). Complex I was inactivated upon CL loss in bovine heart, 
and was only restored upon exogenous addition of CL. 22% of CL loss have resulted in 
diminishing 15% of complex I activity in rat brains (Chicco and Sparagna, 2006; Paradies et al., 
2014). CL oxidation by ROS have also been shown to inactivate complex I (Paradies et al., 
2014). This effect was encountered upon the addition of exogenous CL (Paradies et al., 2014). 
We found that acute administration of 1 µM CL have significantly decreased the mitochondrial 
respiration carried by complex I. These results were intensified upon the administration of 10 
µM CL, suggesting a dose-effect (unpublished data). 
Complex II, also known as succinate dehydrogenase, oxidized succinate from the krebs cycle 
and provides electrons to the electron transport chain (Paradies et al., 2014). The presence of CL 
in the phospholipid environment of complex II is required for the stability and enzymatic activity 
for the complex (Paradies et al., 2014). CL presence around complex II seems to restrict ROS 
production, even though this remains unclear (Paradies et al., 2014).  
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CL stabilizes the quaternary structure of complex III, also known as ubiquinol-cytochrome c 
oxido-reductase (Haines and Dencher, 2002; Chicco and Sparagna, 2006; Paradies et al., 2014). 
Multiple CL molecules bind to complex III to stabilize and maintain its enzymatic activity 
(Haines and Dencher, 2002; Paradies et al., 2014). In the absence of CL, the complex was 
destabilized and its enzymatic activity was significantly diminished (Chicco and Sparagna, 2006; 
Paradies et al., 2014). CL oxidation by ROS also been inactivates complex III (Paradies et al., 
2014). Complex III full activity and stability was rescued only upon the administration of CL, 
signifying the importance of CL and its association to complex III (Paradies et al., 2014).  
Complex IV, also known as cytochrome c oxidase, tightly binds to three CL molecules through 
CL-specific binding sites (Paradies et al., 2014). Complex IV was also found to be stabilized by 
and associated with unsaturated CL molecules for its optimal enzymatic activity (Haines and 
Dencher, 2002; Chicco and Sparagna, 2006; Paradies et al., 2014). Absence of CL has been 
shown to destabilize complex IV and reduced its activity (Paradies et al., 2014). CL peroxidation 
by ROS also inactivates complex IV (Paradies et al., 2014). Its activity was rescued upon the 
addition of exogenous CL (Paradies et al., 2014). 
Complex V, also referred to as F0F1 ATP-synthase, uses proton gradient-derived energy to 
phosphorylate ADP into ATP (Paradies et al., 2014). In complex V, at least four sites were found 
to bind exclusively to CL with high affinity (Chicco and Sparagna, 2006; Paradies et al., 2014). 
Even though the exact contribution of CL to complex V is not yet well studied, but it is evident 
that CL supports the enzymatic activity of complex V (Haines and Dencher, 2002). The removal 
of phospholipids surrounding complex V have significantly diminished its activity, and the 
restoration of complex V activity was more effective upon the addition of CL compared to other 
phospholipids (Paradies et al., 2014).  
It has also been shown that CL is associated with numerous other proteins and that it is required 
for their optimal enzymatic activities (Paradies et al., 2014). These proteins include: 
mitochondrial glycerol-3-phosphate dehydrogenase (Eble et al., 1989; Chicco and Sparagna, 
2006), the phosphate transporter (Chicco and Sparagna, 2006; Paradies et al., 2014), ADP/ATP 
carrier protein (Beyer and Klingenberg, 1985; Chicco and Sparagna, 2006; Haines and Dencher, 
2002; Paradies et al., 2014; Ren et al., 2014), mitochondrial creatine kinase, carbamoyl 
phosphate synthetase I, carnitine/acylcarnitine carrier, nucleoside diphosphate kinase, phosphate 
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transporter, pyruvate transporter, tricarboxylate carrier (Chicco and Sparagna, 2006; Paradies et 
al., 2014). The association strength between CL and these proteins as well as the binding sites 
have not yet been determined (Eble et al., 1989; Chicco and Sparagna, 2006; Paradies et al., 
2014).  
Proton trap: involved in energy metabolism 
The exclusive presence of CL in oxidative phosphorylation molecules, in mitochondria and 
bacteria, suggest its importance in generating ATP (Haines and Dencher, 2002; Claypool and 
Koehler, 2012). Indeed, CL has been reported to serve as a proton trap (Haines and Dencher, 
2002).  
The central glycerol molecule in the CL head group has a free hydroxyl group, which forms an 
internal hydrogen bond with a negatively charged oxygen from one of the two phosphate groups. 
This binding creates a tight bicyclic structure that can trap one proton (Haines and Dencher, 
2002). Mobile CL head group domain laterally shuttles the proton it had trapped from complex I, 
III, and IV to ATP synthase (Haines and Dencher, 2002; Paradies et al., 2014). CL head group 
domain also buffers the change in the acidity across the inner membrane while pumping the 
protons from the matrix to the intermembrane space as CL has a pK2 value above physiological 
conditions (Haines and Dencher, 2002). This allows for the change in potential across the inner 
membrane while buffering the change in pH across the inner membrane (Haines and Dencher, 
2002). Recent work argues that CL PK values are below physiological pH (Kooijman et al., 
2017).  So CL could probably trap two H+ instead of one. 
Mitochondrial permeability transition pore 
Oxidative stress and elevated levels of intra-mitochondrial Ca2+ triggers sudden increase in the 
permeability of the inner mitochondrial membrane through the formation of mitochondrial 
permeability transition pore (MPTP), which consists of multiple proteins including the 
ADP/ATP carriers (Paradies et al., 2014). These pores increase the permeability of solutes below 
1.5 kDa, and diminish the ion gradient across the inner membrane. This affects the inner 
membrane depolarization, and so the oxidative phosphorylation efficiencies, affecting the cell’s 
bioenergetics and viability (Paradies et al., 2014).  
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Exogenous addition of oxidized CL has been shown to induce the opening of the MPTP by 
enhancing Ca2+-sensitivity in the mitochondria (Paradies et al., 2014). The mechanism is not 
very understood, but it was proposed that oxidized CL interacts with MPTP, inducing their 
opening (Paradies et al., 2014). Three CL bind to each ADP/ATP carrier protein, and is required 
for the carrier’s stability and function (Paradies et al., 2014). When CL is oxidized in the 
presence of Ca2+, ADP/ATP carriers are destabilized and their conformation is changed (Paradies 
et al., 2014). This favors MPTP opening and cytochrome c release, which triggers apoptosis and 
promots aging, myocardial ischemia, as well as other diseases (Paradies et al., 2014). 
Cardiolipin-Associated Diseases 
Given the importance of CL in the mitochondria and the impact it has on the cell, it comes to no 
surprise that an alteration in CL composition or abundance disturbs cellular metabolism, and is 
related to many dysfunctions and diseases (Chicco and Sparagna, 2006; Paradies et al., 2014). 
There are three main pathological alterations of CL that are observed in disease conditions: Loss 
of CL content, change in CL composition, and CL peroxidation (Chicco and Sparagna, 2006) – 
all of which are associated with mitochondrial dysfunction and pathologies (Paradies et al., 
2014). 
Several ways can reduce CL content in the mitochondria, including: stimulation of CL 
degradation process, upregulation of ALCAT1 activity, disruption of the Ups1-Mdm35 
dissociation mechanism, impaired CL-biosynthesis enzymes, and reduction in CL-biosynthesis 
precursors (Chicco and Sparagna, 2006; Claypool and Koehler, 2012). 
It is not exactly known why does CL acyl content varies among different cells and organisms, 
but it seems that this variation offers an important biological need to its respective cell (Claypool 
and Koehler, 2012). In the heart, CL acyl chains are primarily composed of linoleic acid (18:2), 
and an alteration in the composition of these chains seem to compromise the function of CL 
(Chicco and Sparagna, 2006; Zhong et al., 2014). A decrease in linoleic acid  CL bioavailability 
can be due to a dysfunction of the CL remodeling enzymes (Chicco and Sparagna, 2006). A 
decrease in the dietary intake of linoleic acid could also account for a decrease in linoleic acid 
CL bioavailability, affecting CL function in the heart (Chicco and Sparagna, 2006). 
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Due to the polyunsaturated acyl chains in CL, CL is susceptible to peroxidation by ROS (Chicco 
and Sparagna, 2006). Peroxidation affects CL integrity and functions, making it more susceptible 
to degradation by phospholipases, which decreases the CL pool and triggers cell apoptosis 
(Chicco and Sparagna, 2006; Claypool and Koehler, 2012; Zhong et al., 2014).  
Barth syndrome 
Barth syndrome is an X-linked disease, and is characterized by a myopathic cardiac and skeletal 
mitochondria that can be lethal (Chicco and Sparagna, 2006; Claypool and Koehler, 2012). Barth 
syndrome is associated with a mutation in the tafazzin gene, which is essential for CL 
remodeling and maturation (Chicco and Sparagna, 2006). This causes Barth syndrome patients to 
have reduced amounts of the mature tetra-linoleoyl CL species, and have high 
monolysocardiolipin and immature CL levels relative to the total CL pool, which is also reduced 
(Chicco and Sparagna, 2006; Claypool and Koehler, 2012).  Dysfunctional CL results in an 
abnormal mitochondrial ultrastructure (Claypool and Koehler, 2012). Additionally, yeast cells 
with tafazzin deletion have accumulated oxidatively damaged proteins, which indicates an 
increase in ROS production by the mitochondria (Claypool and Koehler, 2012). However, it 
remains under debate to whether CL dysfunction causes excessive ROS production or vice versa 
(Claypool and Koehler, 2012). It is possible that decreasing unsaturated CL is a defense 
mechanism against cellular apoptosis since polyunsaturated CL are more prone to peroxidation 
by ROS. 
Exogenous addition of 18:2 CL to fibroblasts from Barth syndrome patients have rescued the CL 
pool in a dose and time dependent manner, proposing a potential treatment for Barth syndrome 
(Chicco and Sparagna, 2006). Mitochondrial function was not tested upon the administration of 
CL, so further research is required (Chicco and Sparagna, 2006).   
Ischemia and Reperfusion 
It is well-established that ischemia and reperfusion (I/R) causes oxidative injury by ROS, which 
leads to phospholipid peroxidation (Chicco and Sparagna, 2006). Peroxidized phospholipids are 
hard to detect, and are more susceptible to hydrolysis by phospholipases, eventually this causes 
their loss (Chicco and Sparagna, 2006). I/R results in phospholipids loss from cardiomyocytes 
(Chicco and Sparagna, 2006). Interestingly, CL loss appear to exceed the loss of other 
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phospholipids from these cardiomyocytes (Lesnefsky et al., 2001; Chicco and Sparagna, 2006; 
Paradies et al., 2014). CL was lost from the mitochondria of the subsarcolemma, which are 
located beneath the interfibrillar and plasma membrane, but not from the interfibers, which are 
located between the myofibrils (Lesnefsky et al., 2001; Chicco and Sparagna, 2006). CL loss had 
a drastic effect on mitochondrial respiration (Lesnefsky et al., 2001; Chicco and Sparagna, 
2006), especially on the function of complex IV – even though complex VI abundance remained 
unchanged (Chicco and Sparagna, 2006). Restricting mitochondrial ROS production in heart and 
skeletal muscles have restored CL levels after I/R, offering a potential therapeutic (Chicco and 
Sparagna, 2006). 
The CL tetra-linoleoyl composition was unaffected by I/R (Lesnefsky et al., 2001; Chicco and 
Sparagna, 2006). CL biosynthesis was also affected by I/R, as CDP-DAG formation was 
interrupted (Chicco and Sparagna, 2006).  
Heart Failure 
A loss in CL pool, 18:2 CL content, and a decrease in CL biosynthesis were observed during 
heart failure (Chicco and Sparagna, 2006; Sparagna and Lesnefsky, 2009). Data has suggested 
that a change in CL composition occurred as a response to heart failure in both, interfibrillar and 
subsarcolemmal mitochondrial (Chicco and Sparagna, 2006). Further, a group of scientists found 
that CL tetra-linoleoyl content and oxidative phosphorylation activity had decreased a few 
months before developing heart failure in rats. This raises the question to whether loss of 18:2 
CL content is a consequence or a cause of heart failure. Contrary, hypertension seemed to 
increase the total CL content relative to other phospholipids in rats (Chicco and Sparagna, 2006). 
Atherosclerosis  
CL has been found to affect aortic cells such as endothelial cells (Carnevale and Bergdahl, 2015) 
and vascular smooth muscle cells. Endothelial cells are involved in a physiological process 
called angiogenesis, which forms new capillaries from pre-existing blood vessels. Angiogenesis 
is important during ischemic conditions to promote healing (Carmeliet, 2003). This process was 
significantly suppressed by the addition of physiological CL concentrations in a dose-dependent 
manner (Cernevale and Bergdahl, 2015). This indicates that CL has anti-proliferative properties 
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on vascular endothelial cells, and that CL disrupts endothelial cells migration and degradation of 
the basement membrane (Carnevale and Bergdahl, 2015).   
While the main function of vascular smooth muscle cells is to contract in the blood vessels, they 
possess the ability to switch into a proliferative, migratory phenotype that contributes to 
atherosclerosis development as a response to environmental cues. This phenotypic switching 
from the contractile phase to the migratory and proliferative phase is a hallmark in 
atherosclerosis progression and persistence. Recent studies have shown that the migration of 
vascular smooth muscle cells was hindered in the presence of CL, while no effect was observed 
in their proliferation in the presence of CL (unpublished data). This indicates that CL affects the 
early stages of the vascular smooth muscle cells phenotypic switching since migration occurs at 
an early stage compared to proliferation  (Louis and Zahradka, 2010). Taken together, it seems 
that CL could potentially play a protective role against atherosclerosis development since it 
diminishes vascular smooth muscle cells migration, preventing the advancement of the disease. 
CL could also play a role in energy preservation, since it blocks angiogenesis, a process that 
would have little significance in the absence of atherosclerosis that contributes to ischemia.  
Thyroidism 
Thyroid hormones promote mitochondrial respiration, and lipid metabolism (Chicco and 
Sparagna, 2006). They also stimulate CL synthase, PG synthase, and MLCLAT (Chicco and 
Sparagna, 2006). Thus, hyperthyroidism increases the total CL pool content and the activity of 
the oxidative phosphorylation complexes, whereas CL content and complexes activity were 
reduced in hypothyroidism (Chicco and Sparagna, 2006). Whether an alteration in thyroid 
activity affects CL tetra-linoleoyl content remains on debate (Chicco and Sparagna, 2006).  
CL content and the complexes activities were replenished in hypothyrodism-induced rat models 
upon the administration of thyroid hormone (Chicco and Sparagna, 2006). This supports the 
importance of the thyroid hormone for CL metabolism and mitochondrial bioenergetics, and 
provides potential therapeutics for hypothyroidism (Chicco and Sparagna, 2006).  
Neurodegenerative Disease 
Free radical stress in rats initiate phospholipid peroxidation. Phospholipid peroxidation results in 
CL loss in aging brains, and is associated with mitochondrial dysfunction and neuronal loss in 
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the substantia nigra. This neuronal loss contributes to neurological diseases such as Parkinson’s 
disease (Chicco and Sparagna, 2006). Parkinson’s disease is associated to mutations in the α-
synuclein-coding gene (Chicco and Sparagna, 2006), and the lack of α-synuclein has been 
associated with 22% reduction of the total CL pool in brain, a reduction in CL containing 
polyunsaturated acyl chains, reduction in a CL-biosynthesis precursor, and an increase in CL 
containing saturated acyl chains. No change was observed in the brain content for other 
phospholipids (Chicco and Sparagna, 2006). Further, complex I and III activities were reduced 
by 15% as a response to these changes in CL content and composition (Chicco and Sparagna, 
2006).  
Diabetes 
CL studies on diabetic rat models is inconclusive (Chicco and Sparagna, 2006). In type I diabetic 
rat models, CL content seemed to have decreased in the brain, unaffected in the heart, and 
increased in the liver (Chicco and Sparagna, 2006). CL biosynthesis and remodeling enzymes 
were unaffected in the heart (Chicco and Sparagna, 2006). So, although it seems that diabetes 
might not have an effect on CL in the heart, other organs that are influenced by diabetes should 
be investigated for their CL content and composition (Chicco and Sparagna, 2006).  
Lung injury in pneumonia 
CL is present in alveolar surfactant, and it covers up to 1-2% of its surface. Low amounts of CL 
are found in healthy lungs' fluid, while CL level is high in injured and pneumonic lungs (Ray et 
al., 2010). Increased CL concentration has been suggested to be directly linked to ATP8b1 
mutations, which binds and translocates CL from the outer to the inner leaflet of membrane 
bilayers (Ray et al., 2010). In the lung fluid, CL decreases epithelial cell viability (Ray et al., 
2010). CL also inhibits the surfactant even at low concentrations (~2 mol%) by impairing the 
major surfactant phospholipid, dipalmitoylphosphatidylcholine, disrupting the lung structure and 
function (Ray et al., 2010). This leads to high surface-tension pulmonary edema and makes the 
lungs more prone to infections by bacteria (Ray et al., 2010). It has also been proposed that 
bacteria might degrade Atp8b1 transporters, disrupt the catalytic function of Atp8b1, or mask the 




Aging relates to hydrogen peroxide production in rat hearts (Chicco and Sparagna, 2006). This 
oxidative stress causes CL peroxidation and a decline in the CL content, contributing to the 
decrease in mitochondrial activity and dysfunction observed in aging (Chicco and Sparagna, 
2006). Loss of 18:2 CL and an increase in other polyunsaturated acyl chains were also observed 
in aging rodent heart and liver (Chicco and Sparagna, 2006). This makes CL more susceptible to 
peroxidation and hydrolysis by phospholipases (Chicco and Sparagna, 2006). In age-dependent 
CL loss experiments, it was revealed that CL loss correlates with a reduction in the activity of 
adenine nucleotide transporters, pyruvate carrier, phosphate transporter, carnitine-acylcarnitine 
transporter, and complex IV (Chicco and Sparagna, 2006).  
Dietary 18:2 Deficiency 
Dietary fatty acids was found to influence CL acyl chain composition in the heart, kidney, liver, 
and brain within hours of consuming the fatty acids (Chicco and Sparagna, 2006). 18:2 CL 
content and mitochondrial respiration in the heart were drastically affected proceeding an 18:2-
deficient intake for a month, while 18:2-CoA supplements have restored CL biosynthesis and 
remodeling (Chicco and Sparagna, 2006). Altering dietary fatty acid content provides a tool to 
study the influence of various CL compositions on mitochondrial proteins and activity (Chicco 
and Sparagna, 2006). 
Chronic Ethanol Consumption 
Chronic ethanol consumption has been shown to reduce tetra-lineoyl CL level in liver 
mitochondria (Chicco and Sparagna, 2006). This might be through disturbing CL remodeling or 
CL precursors availability, even though the mechanism has not yet been confirmed, and further 
investigation is required (Chicco and Sparagna, 2006).  
